AP318A - Benzofuran derivatives - Google Patents

Benzofuran derivatives Download PDF

Info

Publication number
AP318A
AP318A AP9200389A AP9200389A AP318A AP 318 A AP318 A AP 318A AP 9200389 A AP9200389 A AP 9200389A AP 9200389 A AP9200389 A AP 9200389A AP 318 A AP318 A AP 318A
Authority
AP
ARIPO
Prior art keywords
group
bromo
methyl
imidazole
phenyl
Prior art date
Application number
AP9200389A
Inventor
Barry Clive Ross
David Middlemiss
David Ian Carter Scopes
Torquil Ian Maclean Jack
Kevin Stuart Cardwell
Michael Dennis Dowle
Duncan Bruce Judd
Stephan Paul Watson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of AP318A publication Critical patent/AP318A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Description

This invention relates to benzofuran derivatives, processes for their preparation and pharmaceutical compositions containing them.
According to a first aspect of the invention we provide a compound of the general formula (I):
BENZOFURAN DERIVATIVES
Het-CHj
or a physiologically acceptable salt, solvate (e.g. hydrate) or metabolically labile ester thereof in which
R1 represents a hydrogen atom or a halogen atom or a group selected from C1_6alkyl, C2_galkenyl, fluoroCj^galkyl, C1_galkoxy ,-CHO, -CO2H or -COR2;
R represents a group selected from C1_galkyl, C2_galkenyl, Cj-galkoxy or the group -NR13R14;
R represents a group selected from -CO2H, -NHSO2CF3 or a C-linked tetrazolyl group;
R4 and R^ which may be the same or different each independently represent a hydrogen atom or a halogen atom or a C1_galkyl group;
Het represents the group
CV323/C
- 2 R6 represents a hydrogen atom or a group selected from C1_galkyl, C2_6alkenyl, C 1 _ 6 a 1 k y 11 h i o , C^alkoxy, C3_7cyc1oa 1ky1 or C3_7cycloalkylC1_4alkyl;
R7 represents a hydrogen atom or a halogen atom or a group selected from cyano, nitro, C1_galkyl, C2_galkenyl, fluoroC3_ga 1ky1, -(CH2)mR9, -(CH2)nCOR10, -(CH2)pNR1XCOR12, C3_7eyeloa1ky1 or
C3_7cycloalkylC1_4alkyl;
R8 represents a hydrogen atom or a halogen atom or a group selected from cyano, nitro, C1_galkyl, C2_galkenyl, fluoroCj_6alkyl, ~(CH2)raR9, -(CH2)nCOR10 or -(CH2)pNR11COR12;
R9 represents a hydroxy or C|_galkoxy group;
R10 represents a hydrogen atom or a group selected from hydroxy,
C3_galkyl, C1_galkoxy, phenyl, phenoxy or the group -NR13R14;
R11 represents a hydrogen atom or a C1_galkyl group;
R12 represents a hydrogen atom or a group selected from C3_galkyl, C3_galkoxy, phenyl, phenoxy or the group -NR33R^4;
R13 and R^4, which may be the same or different, each independently represent a hydrogen atom or a C3_4alkyl group or -NR13R14 forms a saturated heterocyclic ring which has 5 or 6 ring members and may optionally contain in the ring one oxygen atom;
m represents an integer from 1 to 4, preferably 1 or 2, especially l;
2θ n represents zero or an integer from 1 to 4, preferably zero, 1 or 2, especially zero or 1; and p represents an integer from 1 to 4, preferably 1 or 2;
with the proviso that when R8 represents a hydrogen atom or a group selected from C3_galkyl, C2_galkenyl or C1_galkylthio, R7 represents a group selected from C3_7cycloalkyl or C3_7cycloalkylC1_4alkyl.
In a further or alternative aspect of the present invention,
R^3 and R^4, which may be the same or different, each independently represent, in addition to those groups defined above in general formula (I), a group selected from C5_galkyl, fluoroC1_galkyl, C3_7cycloalkyl, C3_7cycloalkylC1_4alkyl, -(CH2)qR15 or -SO2R15,
3θ wherein R15 represents an aryl group such as a phenyl or pyridinyl group and q represents an integer from 1 to 4, preferably 1 or 2,
AP Ο Ο Ο 3 1 8
CV323/C
- 3 Where a compound of general formula (I) is optically active, said formula (I) is intended to cover all enantiomers, diastereoisomers and mixtures thereof including racemates. Where a compound of the present invention contains one or more double bonds, these may exist in the cis or trans configuration. Furthermore, where such geometric isomers exist, formula (I) is intended to cover mixtures thereof.
The invention also includes within its scope the solvates, especially the hydrates of compounds of general formula (I).
Within the above definition the term 'alkyl' 'alkoxy' or 'alkylthio' as a group or part of a group means that the group is straight or branched. The term 'alkenyl' as a group or part of a group means that the group is straight or branched and contains at least one carbon-carbon double bond. The term 'cycloalkyl' as a group or part of a group may be, for example, a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl group.
The terra 'halogen' means a fluorine, chlorine, bromine or iodine atom.
The term 'fluoroCj_galkyl' means a Cj_galkyl group in which one or more hydrogen atoms have been replaced by a fluorine atom, for example, -CH2CF3. Particularly preferred are 'perfluoroC1_3alkyl' groups meaning a fully fluorinated Cj_3alkyl group, i.e.
2q trifluoromethyl, pentafluoroethyl, heptafluoropropyl or heptafluoroisopropyl.
Within the above definition when -NR^^R^4 represents a saturated heterocyclic ring, this contains 5 or 6 ring members, one of which may be an oxygen atom. Suitable heterocyclic groups are a pyrrolidino, piperidino or morpholino group.
A preferred class of compounds of general formula (I) is that wherein R6 is a hydrogen atom, a C3_^alkyl, especially a C2_5alkyl, group, a C3_5alkenyl group, a Cj_galkoxy group, a C3_7cycloalkyl group or a C3_7cycloalkylC1_4alkyl group. Particularly preferred substituents are an ethyl, n-propyl, or n-butyl, especially an ethyl, group, a but-l-enyl group, an ethoxy group, a cyclopropyl or cyclobutyl group or a cyclopropyImethyl group.
Another preferred class of compounds of general formula (I) is
CV323/C
- 4 Cj.galkyl, C 3 _ γ c y c 1 ο a 1 k y 1 or C 3 _ 7 cy c 1 oa 1 ky 1C 3 _ 4 a 1 ky 1 . In particular, R7 represents a chlorine atom or a methyl, ethyl, propyl, cyclopropyl, cyclobutyl or cyclopropylmethyl group.
Another preferred class of compounds of general formula (I) is that wherein R8 represents a group selected from -(CH2)raR9 or 10 9
-(CH2)nCOR . In particular, R represents a hydroxy or C|_6alkoxy group, and preferably a hydroxy, methoxy, ethoxy, propoxy, or butoxy, group, and especially a hydroxy or methoxy group. R20, in particular, represents a hydrogen atom or a hydroxy, C3_galkoxy or -NR22R2^ group (especially wherein R22 and R2^ each independently represent a hydrogen atom or a C|_4alkyl group), and preferably a hydrogen atom or a hydroxy, methoxy, ethoxy, propoxy, butoxy, amino, methylamino or ethylamino group, and especially a hydrogen atom or a hydroxy, methoxy, amino, methylamino or ethylamino group. Preferably m is 1 or 2, and n is zero, 1 or 2 especially zero or 1, most especially zero.
In particularly preferred embodiments of the present invention, R6 represents an ethoxy, cyclopropyl, cyclobutyl or cyclopropylmethyl group, R7 represents a chlorine atom or a methyl
Q or ethyl group and R represents a group selected from -CH2OH, -CHO, -ch2och3, -co2h, -co2ch3, -co2ch2ch3, -conh2, -conhch3 or -conhch2ch3.
In a further particularly preferred embodiment of the present invention R8 represents a C3_5alkyl group such as an ethyl or propyl group, R7 represents a cyclopropyl, cyclobutyl or cyclopropylmethyl 0 group and R represents a group selected form CH2OH, CHO, CH2OCH3, CO2H, CO2CH3, CO2CH2CH3, CONH2, CONHCH3 or CONHCH2CH3.
A yet further preferred class of compounds of general formula (I) is that wherein R2 represents a hydrogen atom or a halogen atom or a group selected from C16alkyl, C^^alkoxy or fluoroC3_6alkyl, and in particular a hydrogen atom or halogen atom or a C3_3alkyl group. Especially preferred are compounds wherein R2 is a bromine atom.
Conveniently, in the compounds of general formula (I), the group Het-CH2- is attached at the 5- or 6-position on the benzofuran ring, and especially the 5-position.
AP Ο Ο Ο 3 1 8
CV323/C
- 5 Still conveniently, in the compounds of general formula (I), R4 and r5 may each independently represent a hydrogen atom or a halogen atom. In particular R4 and R^ each represent hydrogen atoms.
Particularly preferred compounds of the invention include:
1-((3-Bromo-2-(2-(lH-tetrazol-5-yl) phenyl]-5-benzofuranylJmethyl]-2cyclopropy1-4-me thyl-ΙΗ-imidazole-5-carboxylie acid;
1-((3-Bromo-2-(2-(((trifluoromethyl) sulphonyl]amino J phenyl)-55 ben zofuranyl Jme thyl)- 2-cyclopropyl-4-methyl-lH^-imi dazole-5carboxamide;
1-((3-Bromo-2-(2-(((trifluoromethyl) sulphonyl) amino]phenyl)-5benzof uranyl ] methyl J -2-cyclopropy1-N, 4-dimethyl-IH-imidazo le-5carboxamide;
1-((3-Bromo-2-[2-(((trifluor ome thyl) sulphonyl) amino]phenyl]-5benzofuranyl (methyl)-2-cyclopropyl-N-ethyl-4-methyl-lH-imidazole-5carboxamide;
1-(( 3-Bromo-2 -(2-(lH-tetrazol-5-yl) phenyl ] -5-benzof uranyl Jmethyl]-4chloro-2-cyclopropyl-lH-imidazole-5-carboxylic acid;
1-((3-Bromo-2-(2-(((trifluoromethyl) sulphonyl J amino]phenyl)-5benzofuranyl(methyl]-4-chloro-2-cyclopropyl-IH-imidazole-5carboxamide;
1-((3-Bromo-2-[2-((( trifluoromethyl (sulphonyl)amino]phenyl]-5benzofuranyl (methyl)-4-chloro-2-cyclopropyl-N-methyl-lH-imidazole-5carboxamide;
1-((3-Bromo-2-(2-((( trifluoromethyl (sulphonyl)amino]phenyl )-5benzofuranyl (methyl ]-4-chloro-2-cyclopropyl-N-ethyl-lH-imidazole-5carboxamide;
1-(( 3-Bromo-2-( 2-( lH-tetrazol-5-yl (phenyl ] -5-benzofuranyl (methyl )-222 cyclopropylmethyl-4-methyl-lH-imidazole-5-carboxylic acid;
1-((3-Bromo-2-(2-((( trifluoromethyl ( sulphonyl]amino Jpheny1)-5benzofuranyl ]methyl) -2-cyclopropyImethy l-4-methyl-lH-imidazole-5carboxamide;
1-((3-Bromo-2-[2-(((trifluoromethyl) sulphonyl J amino JphenylJ-5benzofuranyljmethyl)-2-cyclopropy lraethyl-N, 4-dimethyl-lH-imidazole3θ 5-carboxamide;
1-((3-Bromo-2-[2-(((trifluoromethyl) sulphonyl]aminojpheny1]-5benzof uranyl (methyl ]-2-cyclopropylmethyl-N-ethyl-4-methyl-lHimidazole-5-carboxamide;_ _
BAD ORIGINAL
CV323/C
1-((3-Bromo-2-[2-(lH-tetrazol-5-yl)phenyl]-5-benzofuranyl]methyl]-4chloro-2-cyclopropylmethyl-lH-imidazole-5-carboxylic acid;
1-((3-Bromo-2 -[2-(({tri fluoromethyl)3ulphonyl]amino]phenyl]-5benzof urany1]methyl]-4-chior0-2-eyelopropylmethy1-N-methyl- 1Himidazole-5-carboxamide;
1-((3-Bromo-2 -[2-(((trifluoromethyl) sulphonyl]amino]phenyl]-5benzofuranyl]methyl]-4-chloro-2-eyelopropylmethy1-N-ethyl-1H5 imidazole-5-carboxamide;
1-((3-Bromo-2 -[2-(((trifluoromethyl) sulphonyl]amino] pheny1]-5benzofuranyl]methyl]-4-chloro-2-cyclopropylmethy1-1H-imidazole-5carboxamide;
1-(( 3-Bromo-2-[2-(lH-tetrazol-5-yl) phenyl]-5-benzofuranyl]methyl] -210 ethoxy-4-methyl-lH-imidazole-5-carboxylic acid;
1-((3-Bromo-2-(2-(((trifluoromethyl) sulphonyl]amino]pheny1]-5benzofuranylJmethyl]-2-ethoxy-4-methyl-lH-imidazole-5-carboxamide; 1-((3-Bromo-2 -[2-((( tri fluoromethyl)sulphonyl]amino]pheny1J — 5 — benzofuranyl] methyl ]-2-ethoxy-l£, 4 -dimethyl- lH^-imidazole-5carboxamide;
1-((3-Brorao-2-[2-(((trifluoromethyl) sulphonyl]amino]phenyl]-5benzofuranyl]methyl]-2-ethoxy-N-ethyl-4-methyl-ΙΗ-imidazole-5carboxamide;
1-(( 3-Bromo-2-[2-(1H-tetrazol-5-y1) phenyl]-5-benzofuranyl]methyl]-42q chloro-2-ethoxy-lH-imidazole-5-carboxylic acid;
1-((3-Bromo-2-(2-(((trifluoromethyl) sulphonyl]amino]phenyl]-5benzofuranyl]methyl]-4-chloro-2-ethoxy-lH-imidazole-5-carboxamide; 1-((3-Bromo-2-[2-((( trifluoromethyl) sulphonyl]amino]phenyl]-5benzofuranyl]methyl]-4-chloro-2-ethoxy-N-methy1-1H-imidazole-525 carboxamide;
1-((3-Bromo-2 -(2-((( tri fluoromethyl)sulphonyl]amino]phenyl]-5benzof uranyl ] methyl ] -4 -chloro-2 -ethoxy-N-ethyl- lH_-imida zole-5carboxamide;
1-((3-Bromo-2-[2-((( trifluoromethyl)sulphonyl]amino]phenyl]-5benzofuranyl]methyl]-4-eyelopropylmethyl-2-ethyl-ΙΗ-imidazole-530 carboxamide;
1-(( 3-Bromo-2-[2-(((trifluoromethyl) sulphonyl]aminolphenyl]-5benzofuranyl]methyl] - 4 - eye lopropy lmethy 1-2 -et hy 1-N^-me thy 1-1 H_— imidazole-5-carboxamide; _ _ _ _ _ _
AP 0 0 0 3 1 8
CV323/C
- 7 1-((3-Bromo-2-(2-(((trifluoromethyl)sulphonyl]amino]phenyl]-5benzofuranyl]methyl]-4-cyclopropylmethyl-N,2-diethyl-lH-imidazole-5carboxamide;
1-((3-Bromo-2-(2-(((trifluoromethyl) sulphonyl J amino]phenyl]-5be nzofuranyl] methyl ]-4-cyclobutyl- 2-ethyl -1 H_- imidazole - 5carboxamide;
1-((3-Bromo-2-(2-(((trifluoromethyl) sulphonyl]amino J phenyl] - 5benzofuranyl]methyl]-4-cyclobutyl-2-ethyl-N-methyl-lH-imidazole-5carboxamide;
1-((3-Bromo-2-[2-(((trifluoromethyl) sulphonyl]amino) phenyl]-5benzofuranyl]methyl) - 4-cyclobutyl-N,2-diethyl-lH-imidazole-5carboxamide;
1-([3-Bromo-2-(2-(lH-tetrazol-5-yl)phenyl]-5-benzofuranyl]methyl]-4cyclopropyl-2-ethyl-lH-imidazole-5-carboxylic acid;
1-((3-Bromo-2-(2-(lH-tetrazol-5-y 1) phenyl]-5-benzofurany1]methyl]-4cyclobutyl-2-ethyl-lH-imidazole-5-carboxylic acid;
1-((3-Bromo-2-(2-(lH-tetrazol-5-yl)phenyl]-5-benzofuranyl]methyl]-4cyclopropylmethyl-2-ethyl-lH-imidazole-5-carboxylic acid;
1-((3-Bromo-2-(2-(((trifluoromethyl) sulphonyl]amino]phenyl]-5benzofuranyl] methyl]-4-cyclopropyl-2-ethyl-N-methyl-lH-imidazole-5carboxamide;
1-((3-Bromo-2-(2-(((trifluoromethyl) sulphonyl]amino]phenyl]-5benzof uranyl] me thyl] - 4-cyc lop ropyl-2 - ethyl - lH_-imidazole-5carboxamide;
1-((3-Bromo-2-(2-(((trifluoromethyl) sulphonyl]amino]phenyl]-5benzofuranyl]methyl]-4-cyclopropyl-N,2-diethyl-lH-imidazole-5carboxamide;
and physiologically acceptable salts, solvates and metabolically labile esters thereof.
The physiologically acceptable acid addition salts of the compounds of formula (I) may be derived from inorganic or organic acids. Examples of such salts include hydrochlorides, hydrobromides, sulphates, phosphates, benzoates, methanesulphonates or trifluoroacetates.
The compounds may also form salts with suitable bases. Examples of such salts are alkali metal (e.g. sodium or potassium), alkaline earth metal (e.g. calcium or magnesium), ammonium and substituted
BAD ORIGINAL Λ
I
CV323/C
- 8 ammonium (e.g. dimethylararaonium, triethylammonium, 2hydroxyethyldimethylammonium, piperazinium, Ν , N dimethylpiperazinium, tetralkylaramonium, piperidinium, ethylenediaramonium and choline).
It will be appreciated that, for pharmaceutical use, the salts referred to above will be physiologically acceptable, but other salts may find use, for example, in the preparation of the compounds of formula (I) and the physiologically acceptable salts thereof.
It will be further appreciated that the compounds of general formula (I) may be chemically modified in the form of compounds which in vivo (for example, by enzymic attack) will provide the parent compounds of general formula (I). Such prodrugs may be, for example, physiologically acceptable metabolically labile ester derivatives. These may be formed by esterification, for example of any of the carboxylic acid groups in the parent compound of general formula (I), with prior protection of any other reactive groups present in the molecule. Examples of such esters include lower alkyl esters (e.g. methyl or ethyl esters), alkenyl esters (e.g. vinyl or allyl esters), alkynyl esters(e.g. ethynyl or propynyl esters), alkoxyalkyl esters, (e.g. methoxymethyl or 2-raethoxyethyl esters), alkylthioalkyl esters (e.g. methylthiomethyl esters) haloalkyl esters (e.g. 2-iodoethyl or 2,2,2-trichloroethyl esters), alkanoyloxyalkyl esters (e.g. acetoxymethy1, 1-acetoxyethyl or pivaloyloxymethyl esters), alkoxycarbonyloxyalkyl esters (e.g. 1ethoxycarbonyloxyethyl or 1-methoxycarbonyloxyethy1 esters), aroyloxyalkyl esters (e.g. benzoyloxymethyl or 1-benzoyloxyethyl esters), substituted or unsubstituted aralkyl esters (e.g. benzyl or 4-amidobenzyl esters), substituted or unsubstituted aminoalkyl esters (e.g aminoethyl or 2-N,N-dimethylaminoethyl esters) or hydroxyalkyl esters (e.g. 2-hydroxyethyl or 2,3-dihydroxypropyl esters) .
In addition to the above ester derivatives the present invention includes within its scope compounds of general formula (I) in the form of other physiologically acceptable equivalents, i.e. physiologically acceptable compounds which, like the metabolically labile esters, are converted in vivo into the parent compounds of general formula (I). _ ________·'
...........
AP Ο Ο Ο 3 1 8
CV323/C
According to a second aspect of the present invention we provide a compound of formula (I) or a physiologically acceptable salt, solvate or metabo1ica1ly labile ester thereof for use in therapy.
In particular, the compounds of the present invention may be used in the treatment or prophylaxis of hypertension (for example, essential, malignant or resistant, caused by oral contraceptives, coarctation of the aorta or renal vascular disease) and pulmonary hypertension.
The compounds of the present invention may also be used in the treatment or prophylaxis of congestive heart failure, acute or chronic heart failure, aortic or cardiac insufficiency, postmyocardial infarction, renal insufficiency and renal failure (for example, as a result of diabetic nephropathy, glomerular nephritis, scleroderma or renal crisis), proteinuria, Bartter's syndrome, secondary hyperaldosteronisra, Reynaud's syndrome, cerebrovascular insufficiency, peripheral vascular disease, diabetic retinopathy, atherogenesis and for the improvement of vascular compliance.
They are also potentially useful for the treatment of cognitive disorders such as dementia (e.g. Alzheimer's disease) and other CNS disorders, such as anxiety disorders, schizophrenia, depression and alcohol or drug (e.g. ***e) dependency.
According to a further aspect of the present invention we provide a compound of formula (I) or a physiologically acceptable salt, solvate or metabolically labile ester thereof for use in the treatment of the aforementioned diseases, especially hypertension.
According to another aspect of the present invention we provide a compound of formula (I) or a physiologically acceptable salt, solvate or metabolically labile ester thereof for the manufacture of a therapeutic agent for the treatment of the aforementioned diseases, especially hypertension.
According to a further aspect of the present invention we provide a method of treating the aforementioned diseases, especially hypertension, which method comprises administering an effective amount to a patient in need of such treatment of a compound of formula (I) or a physiologically acceptable salt, solvate or metabolically labile ester thereof.
CV323/C
- 10 It will be appreciated that the compounds of formula (I) or a physiologically acceptable salt, solvate, or metabolically labile ester thereof may advantageously be used in conjunction with one or more other therapeutic agents, such as for example diuretics and/or different antihypertensive agents such as fl-blockers, calcium channel blockers or ACE inhibitors. It is to be understood that such combination therapy constitutes a further aspect of the present invention.
It will be further appreciated that reference herein to treatment extends to prophylaxis as well as to the treatment and relief of established symptoms.
While it is possible that a compound of general formula (I) may 10 be administered as the raw chemical it is preferable to present the active ingredient as a pharmaceutical formulation.
The compounds of formula (I) and their physiologically acceptable salts, solvates and metabolically labile esters may be formulated for administration in any convenient way, and the invention also includes within its scope pharmaceutical compositions comprising at least one compound of formula (I) or a physiologically acceptable salt, solvate or metabolically labile ester thereof adapted for use in human or veterinary medicine. Such compositions may be presented for use in conventional manner in admixture with one or more physiologically acceptable carriers or excipients. The carrier(s) must be 'acceptable' in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
Thus, the compounds according to the invention may be formulated for oral, buccal, parenteral or rectal administration or in a form suitable for administration by inhalation or insufflation. Oral administration is preferred.
Tablets and capsules for oral administration may contain conventional excipients such as binding agents, for example mucilage of starch or polyvinylpyrrolidone; fillers, for example, lactose, microcrystalline cellulose or maize-starch; lubricants, for example, magnesium stearate or stearic acid; disintegrants, for example, potato starch, croscarmellose sodium or sodium starch glycollate; or wetting agents such as sodium lauryl sulphate. The tablets may be
AP Ο Ο Ο 3 1 β
CV323/C
- 11 coated according to methods well known in the art. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example, sorbitol syrup, methyl cellulose, glucose/sugar syrup or carboxymethyl cellulose; emulsifying agents, for example, sorbitan mono-oleate; non-aqueous vehicles (which may include edible oils), for example, propylene glycol or ethyl alcohol; and preservatives, for example, methyl or propyl £-hydroxybenzoates or sorbic acid. The compounds or their salts or esters may also be formulated as suppositories, e.g. containing conventional suppository bases such as cocoa butter or other glycerides. For buccal administration the composition may take the form of tablets or lozenges formulated in conventional manner.
It will be appreciated that both tablets and capsules may be manufactured in the form of sustained release formulations, such that they provide a controlled continuous release of the compounds according to the invention over a period of hours.
The compounds of formula (I) and their physiologically acceptable salts, solvates and metabolically labile esters may be formulated for parenteral administration by bolus injection or continuous infusion and may be presented in unit dose form in ampoules, or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.
For administration by inhalation the compounds according to the invention are conveniently delivered in the form of an aerosol spray presentation from pressurised packs or a nebuliser, with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoro methane, dichlorotetrafluoroethane or other suitable gas. In the
CV323/C
- 12 flf Ϊ Λ Π ft case of a pressurised aerosol the dosage unit may be determined by providing a valve to deliver a metered amount.
Alternatively, for administration by inhalation or insufflation, the compounds according to the invention may take the form of a dry powder composition, for example a powder mix of the compound and a suitable powder base such as lactose or starch. The powder composition may be presented in unit dosage form in, for example, capsules or cartridges of e.g. gelatin, or blister packs from which the powder may be administered with the aid of an inhaler or insufflator.
The pharmaceutical formulations according to the invention may also contain other active ingredients such as antimicrobial agents, or preservatives.
It will be appreciated that the amount of a compound of general formula (I) required for use in treatment will vary not only with the particular compound selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will ultimately be at the discretion of the attendant physician or veterinarian. In general, however, when the compositions comprise dosage units, each unit will preferably contain 5mg to 500mg, advantageously where the compounds are to be administered orally 25mg to 400mg of the active compound. The daily dosage as employed for adult human treatment will preferably range from 5mg to 3g, most preferably from 25mg to lg which may be administered in 1 to 4 daily doses.
The compounds of the invention may be prepared by a number of processes as described below wherein the various groups are as defined for general formula (I) unless otherwise specified.
Thus, according to a further aspect of the present invention we provide a process (A) for preparing the compounds of general formula (I) which comprises treating a compound of general formula (II)
AP Ο Ο Ο 3 1 8
CV323/C
- 13 (wherein L is a leaving group, for example a halogen atom such as chlorine, bromine or iodine, or an alkyl- or aryl3ulphonyloxy group such as methanesulphonyloxy, or p-roluenesulphonyloxy and R^ and Ar are as defined in general formula (I)) with an imidazole of general formula (III)
H (III) g 7 fi (wherein R , R and R° are as defined in general formula (I)) followed by the removal of any protecting groups where present, as described hereinafter.
The preparation of compounds of general formula (I) wherein R^ represents a C3_galkoxy group may also be effected by treating a compound of general formula (II) with an imidazole of general formula (Ilia)
(ΙΠ3) (wherein L' is a leaving group that is displaceable by an alkoxy group under conditions suitable for aromatic nucleophilic substitution) to give a compound of general formula (I) wherein R® is l'. This compound (general formula (I), R® is L') may be converted into a compound of general formula I wherein R6 represents a Cj_galkoxy group by treatment with an appropriate alkoxide.
In both of the above cases, the reaction of the compound of general formula (II) with the imidazole of general formula (III) or (Ilia) is preferably effected under basic conditions, for example, in the presence of sodium hydride, potassium carbonate or sodium methoxide. The reaction is conveniently effected in a solvent such 3q as acetonitrile or an ether e.g. tetrahydrofuran or dioxan, a ketone e.g. butanone or methyl isobutyl ketone, or a substituted amide e.g. dimethylformamide, at a temperature between 0®C and the reflux temperature of the solvent.
BAD ORIGINAL
CV323/C
- 14 In another general process (B) a compound of general formula (I) may be obtained by deprotection of a protected intermediate of general formula (IV)
Het-CHj
GV) (wherein R3, Ar and Het are as defined in general formula (I) except that at least one reactive group is blocked by a protecting group).
The protecting groups may be any conventional protecting groups, for example as described in Protective Groups in Organic Synthesis by Theodora Greene (John Wiley and Sons Inc., 1981). Examples of carboxyl protecting groups include C1-6 alkyl such as methyl or t-butyl, or C7_|Oaralkyl such as benzyl.
When R3 is a tetrazole group, this may be protected with, for example, the trityl group -C(phenyl)3, or a £-nitrobenzyl or 1ethoxyethyl group.
Deprotection to yield the compound of general formula (I) may be effected using conventional techniques. Thus, for example, aralkyl groups may be cleaved by hydrogenolysis in a suitable organic solvent such as an alcohol, e.g. ethanol, in the presence of a noble metal catalyst such as palladium or platinum or an oxide 20 thereof on a support such as charcoal, and conveniently at room temperature and pressure. Carboxyl protecting groups such as alkyl groups may be cleaved by hydrolysis using a base such as an alkali metal hydroxide (e.g. sodium hydroxide or potassium hydroxide) in a suitable solvent (e.g. an aqueous alcohol such as methanol or 25 ethanol) at any suitable temperature up to reflux. Deprotection of the tetrazole group when protected with a trityl group may be effected by acid hydrolysis using trifluoroacetic acid or a mineral acid such as hydrochloric acid optionally in a suitable solvent such as ethanol conveniently at room temperature. Alternatively, when possible, deprotection of the tetrazolyl group can be effected by catalytic hydrogenation as previously described.
In another general process (C) a compound of general formula (I) in which the substituent R3 in the group Ar represents a C-
AP 0 0 0 3 1 8
CVJ23/C linked tetrazolyl group (and the imidazolyl group represented by Het is not substituted by a cyano group), may also be prepared from a compound of general formula (la)
(wherein R^, Ar and Het are as defined in general formula (I) except that in the group Ar, R2 represents a nitrile group) by reaction with a suitable azide such as sodium azide, ammonium azide (preferably prepared in situ from sodium azide and ammonium chloride), trialkyl-(e.g triethyl) ammonium azide (preferably prepared in situ from sodium azide and a trialkylamine salt (e.g. triethylamine hydrochloride)) or tributyl tin azide. The reaction is conveniently effected in a solvent such as xylene at an elevated temperature, such as the reflux temperature of the solvent, for between 1 and 10 days. Where the azide is tributyl tin azide the reaction may conveniently be effected in the absence of a solvent at a temperature between room temperature and 180®C. Such a reaction leaves the tetrazolyl group protected with a tributyl tin group, which can readily be removed using aqueous base or acid. Where aqueous base is used to effect this deprotection, the compound may be treated with an aqueous acid to liberate the free tetrazole.
Compounds of general formula (la) may be prepared by processes analogous to those described herein commencing from a compound of formula (VIII) and a corresponding benzofuran intermediate.
The intermediate compounds of general formula (la) and their acid addition salts are novel compounds and form a further aspect of the present invention.
In another general process (D) a compound of general formula (I) in which the substituent R^ in the group Ar represents -NHSO2CF3, may also be prepared from a compound of general formula (lb)
BAD ORIGINAL
CV323/C
- 16 10 (wherein R3, Ar and Het are as defined in general formula (I) except that in the group Ar, R3 represents an amino group) by reaction with trifluoromethanesulphonic anhydride or trifluoromethylsulphonyl chloride, in a suitable solvent such as a halogenated hydrocarbon e.g. chloroform or dichlororaethane in the presence of a base, e.g. triethylamine.
Compounds of general formula (lb) may be prepared by processes analogous to those described herein commencing from a compound of formula (IX) and a corresponding benzofuran intermediate.
Alternatively, compounds of general formula (lb) may be prepared by a Curtius rearrangement of a compound of formula (I) wherein R3 in the group Ar is -CO2H (provided that this is the only carboxylic acid group in the molecule) using, for example, diphenylphosphorylazide in the presence of a base such as triethylamine and in a solvent such as an alcohol (e.g. tertbutanol) to form a carbamate followed by deprotection of the amine in a conventional manner, for example by acid hydrolysis using hydrochloric acid in a solvent such as ethanol.
Compounds of general formula (lb) may also be prepared by reduction of the corresponding nitro precursor using a reducing agent such as iron, tin or zinc in the presence of acid, for example, hydrochloric acid or acetic acid. The reaction is conveniently effected in a suitable solvent such as an alcohol (e.g. ethanol), water or a mixture thereof, at a temperature between room temperature and the reflux temperature of the solvent.
The nitro precursors are readily prepared using method analogous to those described herein.
The intermediate compounds of general formula (lb), their nitro precurors and their acid addition salts are novel compounds and form a further aspect of the present invention.
In another general process (E) a compound of general formula ft IT (I), in which R represents the group -CONHR·1 , may be prepared by reaction of a compound of formula (XIII)
Het‘-CHj
AP Ο Ο Ο 3 1 8
CV323/C
- 17 (wherein Het^ represents a group of formula
in which R® and R? are as defined in general formula (I) and X is a halogen atom (for example chlorine or bromine), or a hydroxyl or Cj_6alkoxy (for example, methoxy, ethoxy or propoxy) group) with ammonia (R33 = hydrogen), methylamine (R13 - methyl) or ethylamine (R13 = ethyl).
IQ Where X is a halogen atom the reaction is a Schotten-Baumann procedure, preferably being effected in the presence of a base such as aqueous sodium hydroxide or pyridine at a temperature between -20°C and 50°C, preferably between -5°C and room temperature.
Where X is a hydroxyl group the reaction may be effected under standard conditions of amide formation, preferably in the presence of a suitable coupling agent, such as Ν,Ν'-carbonyldiimidazole (CDI) or dicyclohexylcarbodiimide. The reaction is conveniently effected in a solvent such as a substituted amide e.g. dimethylformamide, an ether e.g. tetrahydrofuran, or a halogenated hydrocarbon e.g. dichloromethane at a temperature between 0° and 100°C, and conveniently at room temperature.
Where X is a Cj_galkoxy group, the reaction may be effected in the presence of an amine such as anhydrous methylamine in a sealed vessel at a temperature between room temperature and 100°C.
In the processes (A),(B), (C), (D) and (E) described above, the compounds of general formula (I) may be obtained in the form of a salt, conveniently in the form of a physiologically acceptable salt. Where desired, such salts may be converted into the corresponding free acids or free bases using conventional methods.
Physiologically acceptable salts of the compounds of general formula (I) may be prepared by reacting a compound of general formula (I) with an appropriate acid or base in the presence of a suitable solvent such as acetonitrile, acetone, chloroform, ethyl acetate or an alcohol, e.g. methanol, ethanol or isopropanol.
ORIGINAL 0
CV323/C
- 18 Physiologically acceptable salts may also be prepared from other salts, including other physiologically acceptable salts, of the compounds of general formula (I), using conventional methods.
The intermediate compounds of general formula (II) may be prepared from a compound of formula (V):
using any suitable reagent well known in the art for converting the methyl on the 6-membered ring into the group -CH2L (wherein L is as defined above). Thus, for example, when L is a haloqen atom, a compound of formula (V) can be converted into a compound of general formula (II) using N-chloro amides, tert-butyl hypochlorite or Nbromosuccinimide. Halogenation of the side chain may be catalysed by light, thus the reaction can be illuminated with a suitable artificial light source, and preferably in the presence of a free radical initiator such as azobisisobutyronitrile (AIBN) or benzoyl peroxide.
Compounds of formula (V) wherein R1 is a halogen atom, for example, a bromine atom, may be prepared by halogenation of a compound of formula (V) wherein R1 represents a hydrogen atom, using for example, bromine, in a suitable solvent such as a halogenated hydrocarbon, e.g. carbon tetrachloride.
Compounds of formula (V) may be prepared by reaction of a compound of formula (VI)
(wherein Rla represents a hydrogen atom or a group selected from C1_galkyl or C2_6alkenyl) with a compound of formula (VII)
a
AP 0 0 0 3 1 8
CV323/C
- 19 (wherein Z represents a bromine or iodine atom or a -OSC^CF^ or methoxy group, and are as defined in general formula (I) and R3a is as defined for R3 in general formula (I) or is a protected derivative thereof).
The compound of formula (VI) is first treated with an alkyl lithium compound such as n-butyl lithium at a reduced temperature, for example, between -100°C and 0°C in a solvent such as an ether (e.g. tetrahydrofuran). The mixture is then treated with a trialkyl tin halide compound such as trimethyl tin chloride to produce a compound of formula (Via). Alternatively the lithiated precursor may be treated with a tri-alkylborate compound such as triisopropylborate and the temperature conveniently brought up to room temperature. Subsequently, water may be added and the mixture treated with a mineral acid such as sulphuric acid thus producing a compound of formula (Via)
(Via) (wherein Y represents a trialkyl tin (e.g. trimethyl tin) or a boronic acid group).
The intermediate compound of formula (Via) is then reacted with a compound of formula (VII) in the presence of a palladium (0) compound such as tetrakis(triphenylphosphine) palladium (0) in a solvent such as an ether (e.g. dimethoxyethane), and in the presence of a base such as sodium carbonate or thallium hydroxide. The reaction is conveniently effected at an elevated temperature, such as the reflux temperature of the solvent.
Compounds of formula (V) in which the substituent R3 in the group Ar represents a C-linked tetrazolyl group may be prepared from a precursor of a compound of formula (V) wherein the substituent R3 represents a nitrile group using the reagents and conditions described in process (C).
Similarly, intermediates of formula (VII) wherein R3a represents a C-linked tetrazolyl group may be prepared from a compound of formula (VIII)
BAD ORIGINAL ft
CV323/C (VIII)
Γ * 5 -Ί;· CA
CN z
(followed where necessary by protection of any reactive groups), using methods well-known in the art such as those described in process (C).
Compounds of formula (V) in which the substituent R3 in the group Ar is -NHSO2CF3 may be prepared from a precursor of a compound of formula (V) wherein the substituent R3 is an amine group using the reagents and conditions described in process (D).
Similarly, intermediates of formula (VII) wherein R3a represents -NHSO2CF3 may be prepared from a compound of formula (IX),
(IX) (followed where necessary by the protection of any reactive group) using methods well known in the art such as those described in process (D).
Compounds of formula (V) may also be prepared by a reaction of a compound of formula (X)
OH (wherein R3 is as previously defined with the exception of CHO, COR2, wherein R2 is C^_galkoxy or -NR10R11, and halogen) with a suitably substituted benzene of formula (XI) (Xi) ch2l
AP 0 0 0 3 1 8
CV323/C
- 21 (wherein L is as previously defined and R®*3 is as defined for R^a in formula (VII) or is a nitrile group suitable for subsequent conversion into a tetrazolyl group or is a protected amino or nitro group suitable for conversion into -NHSO2CF3), in the presence of a base such as sodium hydride or potassium carbonate. The formation of the compound of formula (V) is a two step reaction which requires up to one equivalent of base per step. It will be appreciated however that the reaction can be effected in the presence ot two equivalents of base to avoid the need to isolate the intermediate. The reaction is conveniently effected in a solvent such as an ether e.g tetrahydrofuran, an alcohol e.g ethanol or a substituted amide e.g dimethylformamide, at a temperature between room temperature and the reflux temperature of the solvent.
It will be appreciated that compounds of general formula (I) may be interconverted into other compounds of general formula (I). For instance, a compound wherein R^ represents a halogen atom (e.g. bromine atom) may be interconverted into a compound wherein R1 represents a Cj_galkyl group (e.g. an ethyl group). The reaction is effected by the coupling of an acetylene compound (e.g. trimethylsilyl acetylene) in the presence of a palladium catalyst (such as bis(triphenylphosphine)palladium dichloride) in a suitable solvent such as a substituted amine (e.g. ethylamine) at a temperature between room temperature and the reflux temperature of the solvent. Subsequent conversion of the 3-acetylene derivative thus formed to give the required 3-alkyl substituent may be effected by conventional reduction.
Compounds in which R? represents a halogen atom (e.g. a bromine atom) may also be converted into compounds in which R^ represents 9 2 the group -COR' (where R is, for example, a methoxy group) by reaction with carbon monoxide in the presence of a base such as triethylamine, palladium diacetate and 1,3-bis(diphenylphosphine)propane and a suitable alcohol (e.g. methanol). The reaction is conveniently effected in a solvent such as a substituted amide (e.g. dimethylformamide) at elevated temperature and pressure.
Compounds in which R® represents the group -COR^® (where R^® is a hydroxy or a Cj galkoxy group) may be converted into compounds in (BAD ORIGINAL
CV323/C ρ ♦ κ η π η Q A
- 22 ο which R represents a halogen atom (e.g. a iodine atom) by reaction with the chosen halogen in the presence of a suitable base (e.g. sodium hydroxide) and a suitable solvent such as an alcohol (e.g. methanol) or a halogenated hydrocarbon (e.g. dichloromethane). The reaction is conveniently effected at a temperature between room temperature and the reflux temperature of the solvent.
Compounds in which R8 represents the group -COR10 (where R10 is a hydroxy group) may be decarboxylated to give a compound in which R8 is a hydrogen atom by a thermal decarboxylation reaction involving heating the carboxylic acid above its melting point (e.g. between 20° and 60° above its melting point), optionally in a suitable high boiling solvent (e.g. 2,4,6-collidine).
It will be appreciated that apart from the interconversion of one compound of general formula (I) into another, these reactions may also be used in the preparation of suitable intermediates.
Other reactions of intermediates include, for instance, the conversion of compounds of formula (V) in which R1 represents a hydrogen or halogen atom into compounds of formula (V) in which R1 represents the group methyl (via hydrogenolysis of the Mannich 2 . 2 base), -CHO or -COR (wherein R is as defined in general formula (I)) using techniques well known in the art, such as those described in Heterocyclic Chemistry by J.A. Joule and G.F. Smith, Van Nostrand Reinhold Company, London (1972), Heterocyclic Chemistry by A. Albert, 2nd Edition, The Athlone Press, London (1968), Heterocyclic Compounds, Vol. 29 by A. Mustafa, John Wiley and Sons Inc., New York (1974), Heterocyclic Compounds, Vol. 2 by R.C. Elderfield, John Wiley and Sons Inc., New York (1951) and Advances in Heterocyclic Chemistry, Vol. 29 by A.R. Katritsky and A.J. Boulton, Academic Press, New York (1981).
The imidazoles of formula (III) may be prepared as described in European Specification No. 0253310A and in US Patent No. 4355040 or by methods analogous to those described therein. The content of these references is hereby incorporated by reference.
Imidazoles of general formula (Ilia) wherein L' represents a bromine atom may be prepared from an imidazole of general formula (XII) _____
CV323/C
AP 0 0 0 3 1 8
AP by meta 11ation, followed by bromination, of the imidazole 2position. Metallation may be effected by treatment with an alkyl lithium compound such as n-butyl lithium, whilst bromination may be effected by treatment with N-bromosuccinimide. In general formula (XII) AP represents a suitable nitrogen protecting group whilst R7a and R®a represent substituent groups that are unaffected by the metallation and bromination reactions, but may, subsequently be 7 a converted to the groups R and R , if necessary.
Intermediates of formulae (VI), (VII), (VIII, (IX), (X), (XI, and (XIII, are either known compounds or may be prepared by methods analogous to those used for the preparation of the known compounds.
The following examples illustrate the invention. Temperatures are in °C. ’Dried* refers to drying using magnesium sulphate. Thin layer chromatography (T.l.c., was carried out on silica and column chromatography was carried out on silica (Merck 9385 unless otherwise stated), using one of the following solvent systems : A ether:hexane, B - ether :dichloromethane, C dich1oromethane:ethano 1:cοnc. aqueous ammonia, Ddichloromethane:ethyl acetate, E - dichloromethane:ether:acetic acid, F-dichloromethane:methanol, G dichloromethane:methanol: acetic acid, H - ethyl acetate:acetic acid, I - ether:ethyl acetate or J - ethyl acetate:hexane.
Proton n.ra.r. spectra were measured on a Bruker WM250 (250 MHz) spectrometer.
The following abbreviations are used : THF - tetrahydrofuran; DME - dimethoxyethane; AIBN - azobisisobutyronitrile; DMF dimethylformamide; TMEDA - tetramethylethylenediamine; NBS - Nbromosuccinimide; DMAP- 4-dimethylaminopyridine; DEAD - diethyl azodicarboxylate; DMSO - dimethylsulphoxide.
The following abbreviations are used in the Tables of exemplification: Et = ethyl; Pr = propyl; Bu = butyl; Hex = hexyl;
CV323/C
phenyl; Py = 2-pyridinyl; Tet-P = 2-( triphenylmethyl)-2H-tetrazole;
t-BOC = N-tert-butoxycarbonyl.
Intermediate 1
5-Methylbenzof uran-2-boronic acid n-Butyl lithium (35.16ml) was added dropwise to a stirred solution of TMEDA (9.58ml) and 5-methylbenzofuran (8.22g) in ether (250ml) maintaining the temperature below - 60®C throughout. The solution was warmed to about -10®C over 45 minutes and stirred at this temperature for 30 minutes. A precipitate formed on warming. The suspension was cooled and triisopropylborate (43ml) was added, maintaining the temperature below -60°C. The solution was warmed gradually to room temperature before quenching with 2N HCl (70ml). The mixture was extracted with ether (3x50ral) and the combined organic extracts washed with 2N HCl (4x30ml), water (2x30ml) and dried before evaporation to give the title compound as an orange solid (12.75g).
T.l.c. System A (1:1), Rf 0.3.
Intermediate 2
Methyl 2-(5-methyl-2-benzofuranyl)benzoate
A solution of methyl 2-bromobenzoate (11.70g), Intermediate 1 (12.75g) and tetrakistriphenylphosphine palladium (0) (0.5g) in DME (300ml) and 2N aqueous NajCOj (60ral) was heated at reflux with vigorous stirring under nitrogen. After 1.5h a further 500mg of catalyst was added and stirring at reflux under nitrogen continued. After about 5h the reaction was cooled to room temperature and diluted with ether (300ral). The organic layer was separated and washed with water (3x100ml) and dried. Filtration and evaporation gave a yellow oily suspension (19.27g) which was purified by chromatography eluting with System A (1:9) to give a yellow oil (11.06g). This was further purified by Kugelrohr distillation to give the title compound (4.31g).
T.l.c. System A (1:9), Rf 0.5.
Intermediate 3
Methyl 2-(3-bromo-5-methyl-2-benzofuranyl)benzoate
AP Ο Ο Ο 3 1 8
CV323/C
- 25 A solution of Intermediate 2 (0.25g) in carbon tetrachloride (5ml) was cooled to -20°C and treated dropwise with 1M bromine in carbon tetrachloride (0.7ml). Stirring at -20°C was then continued for lh before gradual warming to room temperature. Stirring at room temperature was continued overnight. Cyclohexene (0.1ml) was added dropwise and the solvents were evaporated in vacuo to give the title compound as an orange oil (0.26g).
T.l.c. System A (1:9), Rf 0.45.
Intermediate 4
2-(3-Bromo-5-methyl-2-benzofuranyl)benzoic acid
A solution of Intermediate 3 (2.20g) in methanol (20ml) was treated with aqueous sodium hydroxide (2N;3ml). The solution was heated to reflux and heating was continued for 3h. The solvent was removed in vacuo and the residue diluted with water. The basic aqueous phase was washed with ether (3x30ml) before acidification to pH-2 using 2N HCl. A white suspension formed. This was extracted with ether (4x20ml) and these combined organic extracts dried and evaporated to give the title compound as a pale yellow solid (1.93g).
T.l.c. ether, Rf 0.7
Intermediate 5 2θ l,l-Dimethylethylf2-(3-bromo-5-methyl-2-benzofuranyl) phenyl]carbamate
A solution of Intermediate 4 (lg) in dry dioxan (25ml) was treated with diphenylphosphorylazide (0.65ml), triethylamine (0.42ml) and tert-butanol (0.5ml) before heating to reflux under nitrogen. After
6h the reaction was cooled and solvent evaporated to give an orange oil. Purification by column chromatography, eluting with System A (1:10) afforded the title compound as a cream solid (0.67g).
T.l.c. System A (1:1), Rf 0.8
Intermediate 6
1,1-Dimethylethyl f 2 — f3-bromo-5-(bromomethyl)-2-benzofuranyl] phenyl1carbamate
A solution Of Intermediate 5 (4.29g), NBS (2.9g) and benzoyl peroxide (30mg) in dry carbon tetrachloride (100ml) was heated at
CV323/C
- 26 reflux whilst being irradiated with a 200W lamp for 1.5 hours. The mixture was filtered, and the filtrate was washed with water (2x 100ml). The organic solution was dried, filtered and evaporated to give the title compound (5g).
T.l.c. System A (1:1) Rf 0.73.
Intermediate 7
2-(5-Methyl-2-benzofuranyl)benzonitrile
Intermediate 1 (20g) was added to a stirred solution of 2bromobenzonitrile (10.34g) and tetrakistriphenylphosphine palladium (0) (1.5g) in DME ( 200ml) and 8% aqueous NaHCO-j (50ml) at reflux under nitrogen. Further catalyst (1.5g) was added and the reaction was heated overnight. The reaction was cooled to room temperature and diluted with ether (200ml). The organic layer was separated, washed with water (3x100ml) and dried. Filtration and evaporation gave a white solid which was purified by chromatography eluting with System A (1:9) to give the title compound (10.58g) as a white solid. T.l.c. System A (1:9), Rf 0.45.
Intermediate 7 was also prepared by an alternative two-step reaction:
a) 2-Hydroxy-5-methylbenzaldehyde p-Cresol (lOOg) in dry THF(100ml) was added over 30 minutes dropwise to a mechanically stirred, freshly prepared solution of ethyl magnesium bromide (magnesium (25.Og) and bromoethane (75ml)] in THF (500ml) under nitrogen at a rate which maintained a slow reflux. After a further 30mins toluene (1.21) was added, followed by 1,3dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidone (125ml), and paraformaldehyde (70g). The mixture was then heated at reflux for 16h. The mixture was concentrated by distillation and aqueous hydrochloric acid (2M, 600ml) then added. Water (600ml) was added and the mixture filtered through hyflo, dried and concentrated in vacuo to give a brown oil. The oil was steam distilled and the product extracted from the distillate with ether (1 litre). The organic extract was dried and concentrated in vacuo to give a pale yellow slurry which was triturated with ether at -10°C to give the title compound as colourless needles, (131.4g).
AP Ο Ο Ο 3 1 8
CV323/C
- 27 T.i.c. System A (1:5) Rf 0.5.
b) 2-(5-Methy1-2-benzofurany1)benzonitrile
A solution of the product of step (a) (130g) in dry DMF (400ml) was added dropwise to a solution of sodium methoxide (56.2g) in ethanol (400ml) mechanically stirred under nitrogen. After a further 20mins, a solution of 2-(bromomethyl)benzonitrile (182.2g) in dry
DMF (400ml) was added dropwise. The mixture was then heated to 75®C for 30min. The solution was allowed to cool for lh. A slurry of sodium methoxide (56.2g) in dry DMF (100ml) was added and the mixture heated at reflux for 1.5h. The mixture was concentrated in vacuo and then poured into iced water. The solid was collected, and th en triturated with methanol to give the title compound (Intermediate 7) as a beige solid (149.4g).
T.i.c. System A (1:9) Rf 0.4.
Intermediate 8
5-(2-(5-Methyl-2-benzofuranyl)phenyl1-IH-tetrazole A suspension of Intermediate 7 (94g) in tri-n-butyl tin azide (268g) was heated at 100-125®C for 1.25h under nitrogen. The resulting solution was then heated at 155-160^C for 2h under nitrogen, then poured into a solution of aqueous sodium hydroxide
2θ (0.8N, 3070ml). This solution was extracted with ether. The aqueous phase was acidified to pHl with 5N hydrochloric acid and the resulting precipitate filtered, washed with water and dried under vacuum. The solid was dissolved in ethyl acetate, and the solution was washed with brine and dried. The solvent was evaporated to give the title compound as a buff-coloured solid (100.3g).
T.i.c. System A (1:1), Rf 0.2.
Intermediate 9
5-f 2-(3-Bromo-5-methyl-2-benzofuranyl)phenyll-lH-tetrazole A solution of bromine (58g), in carbon tetrachloride (140ml) was added dropwise over 35min to a mechanically stirred solution of Intermediate 8 (50g) in dry dioxan (2090ml) at room temperature under nitrogen. The resulting solution was stirred at room
CV323/C
- 28 preparation of the product was carried out simultaneously on the same scale as described above, and at this stage they were combined. The solvent was evaporated and the residual brown oil (260g) partitioned between ether and aqueous 2M sodium hydroxide. The alkaline solution was acidified to pHl with hydrochloric acid, then extracted with ethyl acetate. The combined ethyl acetate extracts were washed with brine, dried and evaporated to give a buff solid (125g) which was triturated under hot toluene to give the title compound as a cream coloured solid (101.8g).
T.l.c. ether/petroleum ether/acetic acid (50:50:1), Rf 0.27.
Intermediate 10
5-f 2-(3-Bromo-5-methyl-2-benzofuranyl) phenyl1-2-(triphenylmethyl)2H-tetrazole
Triethylamine (57.4g) was added to a mechanically stirred suspension of Intermediate 9 (lOlg) in dry dichloromethane (2.9 litres) at room temperature under nitrogen. Triphenylmethyl chloride (79.3g) followed by DMAP (l.Og) were added at room temperature and the mixture stirred for 3h under nitrogen. The reaction mixture was washed with water, then brine and dried. The solvent was filtered and concentrated to a volume of about 1.2 litres then filtered through silica (Merck 9385, 14cm diam. column). Elution with dichloromethane gave a colourless solid (158.4g) which was triturated with ether to give the title compound as a colourless solid (147.9g).
T.l.c. (Dichloromethane/hexane 1:1), Rf 0.28
Intermediate 11
5-[2 -f 3-Bromo-5-( bromomethyl )-2-benzofuranyl) phenyl]- 2 (triphenylmethyl)-2H-tetrazole
Intermediate 10 (74g) was dissolved in carbon tetrachloride (2050ml) by heating the suspension to reflux. The resulting colourless solution was allowed to cool to 50®C then NBS (22.lg) was added, followed by benzoyl peroxide (l.lg). The reaction mixture was heated at reflux for 3.25h, under nitrogen, then allowed to cool to room temperature. The reaction mixture was washed with water then brine. Another preparation of the product was carried out
AP Ο Ο Ο 3 1 8
CV323/C
- 29 simultaneously on the same scale as described above, and at this stage they were combined and dried. The solvent was evaporated to give a colourless solid (168g ) which was triturated with ether/methanol (1:1) and filtered to give the title compound as a colourless solid (160.8g).
T.l.c. (Dichloromethane/hexane 1:1), Rf 0.15.
Intermediate 12
Ethyl or-amino-3-oxocyclopropanepropanoate hydrochloride Acetyl chloride (15.35ml, 16.88g) was added to a cooled solution of ethyl a-(hydroxyimino)-0-oxocyclopropanepropanoate (20g) in absolute ethanol (250ml) before being added to a suspension of 5% platinum on carbon (1.85g) in absolute ethanol (150ml). The stirred mixture was then hydrogenated at room temperature and pressure for 5h. The catalyst was filtered off through a pad of hyflo and the filtrate concentrated in vacuo to give, after azeotroping with toluene (2 x 80ral), an off-white solid. This was triturated with ether (500ml) to qive the title compound (14.5g) as a white solid, m.p. 196-197°C.
Intermediate 12 was also prepared by an alternative two-step reaction:
( a) Ethyl 5-cyclopropyl-4-oxazolecarboxylate
A mixture of ethyl isocyanoacetate (13.4g) in THF (65ml) was added dropwise to a stirred solution of potassium tert-butoxide (14.5g) in THF (97ral) at 0°C. Cyclopropanecarboxylic acid chloride (5.4ral) was added dropwise at below 10°C and the solvent evaporated. Water (68ml) and acetic acid (3.4ml) was added to the mixture, then diisopropyl ether (2x150ml) was added and the layers separated. The aqueous layer was further extracted with diisopropyl ether (2x 150ml) and the combined organic extracts were dried. Evaporation of the solvent afforded the title compound as a yellow oil (8.3g). n.m.r. (CDCl3) δ 1.03 (4H,m), 1.34 (3H,t), 2.70 (lH,m), 4.32(2H,q), 7.53 (lH,d).
(b) Ethyl or-amino-0-oxocyclopropanepropanoate hydrochloride Concentrated hydrochloric acid (21.5ml) vas added to a solution of the product of step (a) (9.3g) in ethanol (65ml). The mixture was bad original
F > 1
CV323/C
- 30 heated at 50°C for lh, cooled and the solvent was evaporated. Toluene (3x50ml) was added to the residue and was evaporated after each addition. The residue was triturated with diisopropyl ether (80ml) to give the title compound (Intermediate 12) as a pale brown powder (6.8g) m.p. 158-159°C.
Intermediate 13
Ethyl 4-cyclopropyl-2-ethyl-lH-inu.dazole-5-carboxylate
A solution of Intermediate 12 (14.5g) in absolute ethanol (110ml) was added dropwise over lh to a stirred suspension of ethyl propanimidate hydrochloride (25.lg) and triethylamine (32ml, 22.7g) in absolute ethanol (200ml). After stirring overnight under
IQ nitrogen, the grey suspension was concentrated in vacuo to afford a grey residue which was partitioned between ethyl acetate (250ml), ethanol (50ml), water (200ml) and saturated sodium chloride (100ml). The aqueous phase was further extracted with ethyl acetate (2 x 100ml) and the combined organic extracts were dried and concentrated in vacuo to afford a grey solid (31g). Purification by chromatography eluting with System A (1:3) increasing to (1:1) gave the title compound (3.5g) as a white solid, m.p. 154-155®C.
Intermediate 14
4-Methyl-1-(triphenylmethyl)-lH-imidazole
A suspension of triphenylmethyl chloride in anhydrous DMF (100ml) was slowly added to a stirred solution of 4-methylimidazole (12.30g) and triethylamine (41.8ml) in anhydrous DMF (200ml). After stirring the resultant slurry for ca. 3h it was added to water (750ml) and the solid removed by filtration. The solid was dissolved in dichloromethane (500ml) and residual water separated. The organic solution was dried and evaporated to dryness to give the title compound as a white solid (42.7g).
T.l.c. System C (100:8:1) Rf= 0.71.
Intermediate 15
2-Bromo-4-methyl-l-(triphenylmethyl)-lH-imidazole
A solution of n-butyllithium in hexane (1.55M; 95ml) was added to a stirred solution of Intermediate 14 (40.Og) in freshly distilled THF
AP Ο Ο Ο 3 1 8
CV323/C
- 31 (2500ml) and DUE (500ml) at 5°C under nitrogen. The resulting light orange suspension was stirred at 20®C for lh before cooling to 5®C and dropwise addition of NBS (21.9g) in freshly distilled THF (100ml) to give a buff suspension. After stirring overnight at room temperature water (100ml) was added and the resulting solution concentrated to ca 1000ml. Further water (1500ml) was added and the mixture extracted with dichloromethane (3 x 500ml). The combined extracts were washed with saturated brine (500ml) dried and concentrated in vacuo to give a brown solid. Flash column chromatography eluting with 5% ether in dichloromethane gave the title compound as a white solid (24.0g).
T.l.c. ether: petroleum ether (1:1) Rf = 0.50.
Intermediate 16
2-Bromo-4(5)-methyl-lH-imidazole
A suspension of the Intermediate 15 (23.8g) in 5% acetic acid in methanol (250ml) and freshly distilled THF (50ml) was heated at reflux for ca 2.5h. to give a yellow solution. The mixture was evaporated to dryness to give a yellow/white solid to which water (250ml) was added. The resulting suspension was vigorously stirred for ca 30min before filtration and thorough washing of the solid with water. The combined filtrate and washings were concentrated in vacuo to give the title compound as a light yellow powder (8.20q).
T.l.c. System A (1:1) Rf = 0.18.
Intermediate 17
2-Bromo-4-methyl-ΙΗ-imidazole-5-methanol
37% Aqueous formaldehyde (3.1ml) was added to a solution of Intermediate 16 (4.00g) in water (25ml) and ethanol (50ral) and 2N aqueous sodium hydroxide (12.5ml). After standing overnight the solution was acidified to ca pH8 with 2N hydrochloric acid and concentrated to a small volume (ca 10ml). Saturated brine (100ml, was added and the mixture extracted with (4:1) chloroform/ispropanol (3 x 75ml). The combined extracts were dried and concentrated in vacuo to give a yellow wax. Trituration with ether gave the title compound as a buff powder (3.70g) .
T.l.c. ether Rf = 0.13 bad original
CV323/C
- 32 Intermediate 18
2-Bromo-4-methyl-lH-imidazole-5-carboxaldehyde
Manganese dioxide (7.40g) was added to a stirred solution of Intermediate 17 (1.90g) in (1:1) dichloromethane/1,4-dioxan (100ml) and the resulting suspension heated at reflux under nitrogen overnight. The suspension was filtered through hyflo and the filtrate concentrated in vacuo to give a yellow solid. Trituration with System A (1:1) gave the title compound as a light yellow powder (1.20g).
T.l.c. ether Rf = 0.58.
Intermediate 19
Ethyl 1-[[3-bromo-2-f2-[2-(triphenylmethyl)-2H-tetra2ol-5yllphenyl]-5-benzofuranyl]raethyll-4-cyclopropyl-2-ethyl-lHimidazole-5-carboxylate
A mixture of Intermediate 13 (1.67g), Intermediate 11 (6.76g), and potassium carbonate (1.33g) in dry DMF (20ml) was stirred at room temperature for 18h. The mixture was partitioned between ethyl acetate (3 x 100ml) and brine/water 1:1 (150ml). The combined organic extracts were washed with brine/water 1:1 (3 x 150ral) and dried. The solvent was evaporated to give a pale yellow gum (7g)
2Q which was purified by flash column chromatography eluting with System A (1:1) to give the title compound as a colourless foam (4.32g).
T.l.c. System A (1:1) Rf 0.3.
Similarly prepared was :Intermediate 20
Ethyl 1-(f 3-bromo-2-[ 2-f f1,1-dimethylethoxy)carbonyl) amino)phenyl]5-benzofuranyl]methyl]-4-eye lopropy1-2-ethy1-1H-imida zole-5carboxylate 30 n.m.r. (CDCl3) δ 0.8-1.0(4H,m), 1.23(3H,t), 1.32(3H,t), 1.5(9H,s),
2.58-2.72(3H,m), 4.28(2H,q), 5.65(2H,s), 7.01(lH,dd), 7.1-7.2(2H,m),
7.4-7.5(2H,m), 7.63(lH,dd), 8.17(lH,d).
From Intermediate 13 and Intermediate 6.
AP Ο Ο Ο 3 1 8
CV323/C
- 33 Intermediate 21 — f f3-Bromo-2-[2-[2-(triphenylmethyl)-2H-tetrazol-5-yllphenyI]-5benzofuranylImethyll-2-cyclopropyl-4-methyl-lH-imidazole-5carboxaIdehyde
Intermediate 11 (1.81g) was added to a stirred mixture of 2cyclopropyl-4-methyl-lH-imidazole-5-carboxaldehyde (350mg) and potassium carbonate (320mg) in anhydrous DMF. The resulting suspension was stirred for ca. 36h at room temperature to afford a yellow solution. Water (50ml) was added and the mixture extracted with dichloromethane (3 x 50ml). The combined extracts were washed with water (3 x 50ral) dried and concentrated in vacuo to give a brown oil. Flash column chromatography eluting with ether gave the title compound as a white foam (l.OOg).
T.l.c. ether Rf = 0.42.
Similarly prepared was:intermediate 22
2-Bromo-1-((3-bromo-2- (2-(2-( triphenylmethyl)-2H-tetrazol-5yl)phenyll-5-benzofuranyl]methyl]-4-methyl-1H-imida zole-5carboxaldehyde
T.l.c. ether:hexane:dichloromethane (10:30:100) Rf = 0.53.
From Intermediate 11 (3.70g) and Intermediate 18 (900mg).
Purification by column chromatography eluting with ether:hexane:dichloromethane (10:100:100) gave the title compound as a white foam (1.70g).
Intermediate 23
Ethyl 1-((2-(2-aminophenyl)-3-bromo-5-benzofurany1)methy1)-4cyclopropyl-2-ethyl-lH-imidazole-5-carboxylate
Trifluoroacetic acid (5ml) was added to a stirred solution of Intermediate 20 (2.55g) in dichloromethane (40ral) at 3° under nitrogen. After allowing to warm to room temperature and stirring for 4h. the solution was cautiously neutralised with 8% sodium bicarbonate (50ml), was washed with 8% aqueous sodium bicarbonate (40ml), dried and concentrated in vacuo to afford a dark yellow
CV323/C
- 34 viscous oil (2.15g). Purification by chromatography eluting with ether afforded the title compound (2.0g) as a white foam, n.m.r. (CDCl3) δ 0.9-1.1(m,4H), 1.21(t,3H), 1.31(t,3H), 2.582.62(m,3H), 4.24-4.34(m,4H), 5.62(s,2H), 6.77-7.0(ra,3H), 7.27.3(m,2H), 7.42(d,lH), 7.6(dd,lH).
Intermediate 23 was also prepared by an alternative method:
Intermediate 23 (alternative method)
Ethyl 1—f [2-(2-8ΐηϊηορΗ6ηγ1)-3^ΓθΓηο-5-Ββηζοίυ^ηγ1ΐπ:β^γ1)-4CYclopropyl-2-ethyl-lH-imidazole-5-carboxylate
Iron powder (17g) was added to a stirred solution of Intermediate 74 (40g) ethanol (450ml), water (140ml) and acetic acid (140ml) and the mixture heated at reflux for 1.5h. The mixture was cooled, filtered (celite) and washed with ethanol (2x300ml). The combined filtrate and washings were evaporated to a thick slurry, water (1 litre) was added and the pH adjusted to 9-10 by the addition of solid sodium carbonate. Water (1 litre) and ethyl acetate (1 litre) were added, the mixture filtered (celite) and the organic layer was separated. The aqueous layer was further extracted with ethyl acetate (750ml and 250ml). The combined organic extracts were washed with brine (300ml) and evaporated to a solid which was recrystallised from diisopropyl ether (150ral) to give the title compound as an off-white solid (27.9g).
Assay Found: C,61.5; H,5.3; N,8.2; Br, 15.8;
C26H26BrN3°3 recIuires: C,61.4; H,5.15; N,8.3; Br, 15.7%
Intermediate 24
1-[[3-Bromo-2-(2-f2-(triphenylmethyl)-2H-tetrazol-5-yl)phenyl)-5benzofuranylImethyl]-2-cyclopropyl-4-methyl-lH-imidazole-5carboxylic acid
A solution of 80% sodium chlorite ( 1 . 13g) and sodium dihydrogenorthophosphate dihydrate (1.13g), in water (20ml) was added dropwise to a stirred solution of Intermediate 21 (950mg) in freshly distilled THF (20ml), t-butanol (20ml) and 2-methylbut-2-ene (0.59ml). The mixture was rapidly stirred at room temperature for 48h before concentration to ca 25ml and addition of water (100ml).
CV323/C
AP 0 0 0 3 1 8
- 35 The mixture wae extracted with ethyl acetate ( 3x 100ml) and the combined extracts dried and concentrated in vacuo to give a white foam. Flash column chromatography eluting with 5% acetic acid/5% dichloromethane in ether gave the title compound as a white foam (700mg).
T.l.c. 5% acetic acid in ether Rf = 0.18
Intermediate 25
1-f[3-Bromo-2-[2-f 2-(triphenylmethyl)-2H-tetrazol-5-yllphenyl)-5benzofuranyl]methyll-2-ethoxy-4-methyl-lH-imidazole-5-carboxaldehyde
A solution of Intermediate 22 (l.OOg) and sodium ethoxide (0.43g) in (1:1) ethanol/THF (25ml) was heated at reflux overnight. The solution was concentrated to a small volume (ca 5ral), water (100ml) added and the mixture extracted with dichloromethane (3 x 75ml). The combined extracts were dried and concentrated in vacuo. Flash column chromatography eluting with ether:dichloromethane (2:1) gave the title compound as a yellow foam (400mg).
T.l.c. ether Rf = 0.37.
Intermediate 26
1-f[3-Bromo-2-[2-(2-(trifluoromethyl) sulphonyl]amino)phenyl]-5benzofuranyl]methyl)-4-cyclopropyl-2-ethyl-lH-imidazol-5yl)carbonyl)-lH-imidazole
1.1- Carbonyldiiraidazole (O.73g) was added to a solution of the product of Example 5 (1.7g) in THF (100ml). The resulting suspension was then stirred at room temperature for 60h, filtered and the filtrate was concentrated in vacuo to afford the title compound (1.9g) as a white foam.
T.l.c. System F (15:1), Rf 0.65(Streak).
Intermediate 27
1.1- Dimethylethyl 2-(3-bromo-5-methyl-2-benzofuranyl)benzoate
The title compound was prepared from Intermediate 1 and 1,1diraethylethy1 2-broraobenzoate according to the method of Intermediate 2, followed by bromination according to the method of Intermediate 3.
T.l.c. dichloromethane:hexane (1:2) Rf = 0.3
CV323/C
- 36 + +5 *· '· +. r* ϊ
Intermediate 28
1,1-Dimethylethyl 2-[3-bromo-5-(bromomethyl)-2-benzofurany!]benzoate
The title compound was prepared from Intermediate 27 according to the method of Intermediate 6.
T.l.c. System A (1:10) Rf = 0.4
Intermediates 29 to 36 in Table la were prepared according to the method of Intermediate 19 from Intermediate 6, 11 or 28 and the corresponding imidazole intermediate (Equation la):
Intermediates 37 to 39 in Table lb were prepared according to the method of Intermediate 23 (Equation lb):
Equation lb
Intermediate 40
Ethyl 4-cyclopropy1-1-[ f 2-[2-f f (1,1-dimethylethoxy) carbonyl] aminolphenyl1-3-((trimethylsilyl)ethynyl)-S-benzofuranylImethyl)-2ethy1-1H-imidazole-5-carboxylate
AP 0 0 0 3 1 8
CV323/C
- 37 Trimethylsilylacetylene (8ral) then bis(triphenylphosphine)palladium dichloride (0.86g) and copper (I) iodide (0.26g) were added to a solution of Intermediate 20 (7.0Sg) in diethylamine (40ml). The contents were heated (90*C) in a sealed vessel for 29h. After cooling, the residue was diluted with ethyl acetate (300ml) and washed with water (300ml). The dried organic extract was concentrated in vacuo and the residue purified by flash chromatography eluting with System A (1:3) to give title compound as a yellow foam (2.4g).
T.l.c. System A (2:3) Rf=0.4
Intermediate 41
Ethyl 4-cyclopropyl-l-[[2-(2-(f ( 1, 1-dimethy1ethoxy) carbonyl) amino) phenyl]-3-ethynyl-5-benzofuranyl lmethyl)-2-ethyl-lH-imidazole5-carboxylate
2M Aqueous sodium hydroxide (60ml) was added to a stirred solution of Intermediate 40 (2.38g) in methanol (40ml)/THF (15ml) and stirring continued for 16h at ambient temperature. The resulting mixture was concentrated in vacuo and partitioned between dilute hydrochloric acid (pH4) and ethyl acetate. The dried organic extract was concentrated in vacuo and the residue purified by flash chromatography eluting with System A (3:7) to give the title compound as a yellow foam (1.51g).
T.l.c. System A (2:1) Rf=0.5
Intermediate 42
Ethyl 4-cyclopropy1-1 -([2-|2-|f(l, 1-dimethylethoxy) carbonyl] euni no ] phenyl)-3-ethyl -5-benzof uranyl Imethy ll-2-ethyl-lH-imidazole-5carboxylate
A solution of Intermediate 41 (600mg) in ethanol (35ml) containing 10% palladium on carbon (300mg) was hydrogenated at room temperature and pressure for 17min. The separated organic solution was concentrated in vacuo to give the title compound as a white foam (530rag).
T.l.c. System A (2:1) Rf=0.45
Intermediate 43
ORIGINAL $ *· rCV323/C
- 38 Trimethyl (5-methy1-2-benzofuranyl)stannane n-Butyl lithium (1.57M in hexane, 75ml) was added dropwise to a stirred solution of 5-methylbenzofuran (14g) in dry THF (150ml) at -70* under nitrogen over 45min. The solution was then allowed to warm to -55’ before a solution of trimethyltin chloride (23g) in THF (70ral) was added dropwise. The solution temperature rose to -32*. The cooling bath was removed and the solution was stirred at room temperature for 2h. The solution was diluted with ethyl acetate (250ml) and washed with water (200ml). The organic layer was dried and concentrated in vacuo to afford a yellow liquid (32g). Kugelrohr distillation of this liquid gave the title compound (23.3g) as a colourless liquid, b.p. 115* at 7mbar.
Intermediate 44
Methyl 2-fluoro-6-iodobenzoate
Concentrated sulphuric acid (0.5ml) was added to a solution of 2fluoro-6-iodobenzoic acid (1.03g) in methanol (35ml). After stirring at reflux for 5 days, with two further amounts of cone, sulphuric acid (1ml) being added after 1 and 2 days, the solution was allowed to cool. The reaction mixture was diluted with ethyl acetate (200ml) before being washed with water (2x80ml), 8% aqueous sodium bicarbonate (2x100ml), dried and concentrated in vacuo. Purification by chromatography eluting with System A (1:3) afforded the title compound (0.72g) as an orange oil.
T.l.c. System A (1:1) Rf 0.6
Intermediate 45
Methyl 2-fluoro-6-(5-methy1-2-benzofuranyl)benzoate
Tetrakis(triphenylphosphine) palladium (0) (0.19g) was added to a stirred solution of Intermediate 43 (1.2g) and Intermediate 44 (0.95g) in toluene (30ml). The solution was then stirred at reflux for 3h before being cooled, diluted with ethyl acetate (35ml), washed with water (1x50ml), dried and concentrated in vacuo to afford a red oil (1.7g). Purification by chromatography (Merck 7734) eluting with System A (1:9) afforded the title compound (0.83g) ae a yellow oil.
Assay Found: C,71.9; H,4.35;
AP Ο 0 0 3 1 β
CV323/C
- 39 c17h13fo3 re<3uires: C,71.8; H,4.6%
Intermediates 46 to 48 in Table 2a were prepared according to the method of Intermediate 45 from Intermediate 43 and the appropriate benzoic acid ester (Equation 2a):
Intermediates 49 to 52 in Table 2b were prepared by treatment of Intermediates 45 to 48, respectively, either with bromine in carbon tetrachloride followed by NBS in the presence of benzoyl peroxide as described in Intermediates 9 and 11, to give Intermediates 49 and 52, or with just NBS in the presence of benzoyl peroxide as described in Intermediate 11 to give Intermediates 50 and 51 (Equation 2b):
Equation 2b
Intermediates 53 to 56 and Example 67 in Table 2c were prepared according to the method of Intermediate 19 by reaction of Intermediates 49 to 52, respectively, with the corresponding imidazole intermediate (Equation 2c):
^original
CV323/C
The intermediate imidazoles utilised in these examples may be 10 prepared as follows. Intermediates 57 to 61 in Table 10 were prepared according to the method of Intermediate 13 (Equation 10):
Equation 10
Intermediate 62
Ethyl 2-cyclobutylmethyl-4-(trifluoromethyl)-lH-imidazole-520 carboxylate
A suspension of Intermediate 61 (1.25g) and 4A sieves (1.2g) in toluene (40ral) was refluxed for 60h. The reaction was filtered, washed in with dichloromethane and evaporated to give the title compound as an off-white solid (1.15g), m.p. 136-138°C.
Intermediate 63
4-Cyclopropyl-2-ethyI-IH-imidazole-5-carboxylic acid
A mixture of Intermediate 13 (2g), sodium hydroxide (2N; 35ml) and methanol (40ml) was heated at reflux for 2l/ih before being evaporated. It was then cooled to 0-5’C and hydrochloric acid (35ml) added with stirring. The resulting precipitate was filtered and dried to give the title compound as a white solid (1.4g), m.p. 206’C (decomp.)
AP Ο Ο Ο 3 1 8
CV323/C
- 41 Intermediate 64
1,1-Dimethylethyl 4-cyclopropyl-2-ethyi-ΙΗ-imidazole-5-carboxylate
A suspension of Intermediate 63 (lg) in toluene (10ml) at 80‘C was treated with dimethylformamide di-tert-butyl acetal (4.1g) dropwise over a 5min period. The mixture was cooled and diluted with toluene (50ml). The organic solution was washed with water (50ml), aqueous sodiura carbonate (2M; 50ral) and aqueous lithium chloride (10%w/v;
50ml), dried and evaporated in vacuo to give the title compound as a pink solid (0.57g).
T.l.c. System F (10:1) Rf 0.4
Intermediate 65
2-(Cyclopropylmethyl)-lH-imidazole-5-methanol
Dihydroxyacetone dimer (28.9g), followed by ethyl 2(cyclopropyl)ethanimidate hydrochloride (30g) were cautiously added portionwise to freshly condensed liquid ammonia (200ral) at -78° under nitrogen. The resulting stirred slurry was poured into a cold dry ice autoclave (600ml) and the mixture stirred and heated at 90° (600psi) for 16h. The cooled (dry ice) mixture was poured into cold methanol (500ml) and the mixture concentrated in vacuo to give a brown oil. The crude material was purified by flash column chromatogrpahy eluting with System C (100:8:1) to give the title compound as a colourless solid (14.71g).
T.l.c. System C (100:8:1) Rf 0.2
Intermediate 66
4-chloro-2-(cyclopropylmethyl)-lH-imidazole-5-methanol N-Chlorosuccinimide (12.1g) was added to a solution of Intermediate 65 (12g) in 2-methoxyethanol/dioxan 1:1 (200ml) and the mixture stirred at room temperature, under nitrogen, in the dark for 6h. The solvent was evaporated and the residue triturated under ethyl acetate and filtered to give the title compound as a colourless solid (7.25g).
T.l.c. ether Rf 0.25
Intermediate 67
4-Chloro-2-(cyclopropylmethyl)-lH-imidazole-5-carboxaldehyde
CV323/C activated manganese dioxide (26.5g) was added to a suspension of Intermediate 66 (26.5g) in dichloromethane/1,4-dioxan 2:1 (300ml) at room temperature under nitrogen, and the mixture heated at reflux for 16h. The cooled mixture was filtered through hyflo and the filtrate evaporated to dryness. The residue was triturated under ether (30ml) and filtered to give the title compound as a colourless solid (6.38g).
T.l.c. ether:petroleum ether (1:1) Rf 0.4
Intermediate 68
1-(f 3-Bromo-2-f 2-f((1,1-dimethylethoxy)carbonyl]aminojphenyl)-5benzofuranyl)methyl-4-chloro-2-(cyclopropylmethyl)-lH-imidazole-5carboxylic acid
Intermediate 36 (4g) was treated with a mixture of sodium chlorite (5.58g) and sodium dihydrogen phosphate (5.58g) in water (60ml) according to the method of Intermediate 24, to give the title compound as a colourless foam (4g).
T.l.c. ether Rf 0.45 (streaking to 0.2).
Intermediate 69
Ethyl 1 — f f3-bromo-2-f[(l,l-dimethylethoxy)carbonyl]amino]phenyli-5benzofuranyllmethyl)-4-chloro-2-(cyclopropylmethyl)-lH-imidazole-5carboxylate
DEAD (1.95ml) was added dropwise to a mixture of Intermediate 68 (3.64g), triphenylphosphine (3.25g, and ethanol (1.14g) in dry THF (100ml) at room temperature under nitrogen. The mixture was stirred for 2h, the solvent was then evaporated and the residue purified by flash column chromatography eluting with ether:petroleum ether (1:2) to give the title compound as a colourless foam (3.26g).
T.l.c. ether:petroleum ether (2:1) Rf 0.25.
Intermediate 70
Methyl 2-f 3-bromo-5-(bromomethyl·)-2-benzofuranyl]benzoate A solution of Intermediate 3 (0.26g) in carbon tetrachloride (8ml) was treated with 0NBS (0.134g) and AIBN (lOmg) according to the method of Intermediate 6 to give the title compound as a pale yellow oil (0.19g). _______
AP Ο Ο Ο 3 1 8
CV323/C
- 43 T.l.c. System A (1:9) Rf=0.4
Intermediate 71
5-Methy1-2-( (2-nitrophenyl)methoxy1benzaldehyde
Methanesulphonyl chloride (5.4ml) was added dropwise to a stirred solution of 2-nitrobenzeneaethanol (lO.Og) and triethylamine (10.1ml) in 1,4-dioxane (10ml) at 15-25°c. After 30min the mixture was filtered, washed with 1,4-dioxane (50ml) and the filtrate added to a stirred mixture of 5-methylealicylaldehyde (9.1g) and potassium carbonate (9.9g) in Ν,Ν-dimethylacetamide (50ml). The mixture was stirred at 20°C for 24h, water (160ml) was added and, after a further lh, the mixture was filtered. The filtrate was washed with jq water:1,4-dioxane (1:1? 50ml) and water (150ml) and dried at 40°C in vacuo to give the title compound as a cream coloured solid (15.7g)
m.p. 124°C.
Intermediate 72
5-Methyl-2-(2-nitrophenyl)benzofuran sodium methoxide (0.45g) was added to a suspension of Intermediate 71 (15.0g) in Ν,Ν-dimethylacetamide (75ml) at 25°C and the mixture was stirred for 30mins. Water (120ml) and ethyl acetate (75ml) was added and the aqueous layer was further extracted with ethyl acetate (75ml and 25ml). The combined ethyl acetate extracts were washed with water (75ml) and aqueous sodium chloride (12%, 75ml) and then concentrated to a volume of 25ml. 98% Formic acid (75ml) was added at 40°C and the resulting solid collected by filtration to give the title compound as a yellow solid (13.7g). m.p. 83°C.
Intermediate 73
3-Bromo-5-( bromomethyl· )-2-( 2-nitrophenyl)benzofuran
A mixture of Intermediate 72 (10.Og), NBS (7.1g) and 2,2'-azobis(2methylpropionitrile) (0.26g) in 1,1,1-trichloroethane (100ml) was stirred and heated at reflux for 2.5h. The mixture was cooled and dichloromethane (100ml) was added. Bromine (2.84ml) was added and the mixture stirred at room temperature for 18h. Cyclohexene (10ml) and dichloromethane (100ml) was added, followed by water (100ml), and the mixture stirred for lOmins. The organic phase was v — - r -*· , -τ. *’*2—.——
BAD ORIGINAL
CV323/C
- 44 evaporated, washed with 10% aqueous sodium thiosulphate (100ml) and the combined aqueous washings further extracted with dichloromethane (50ml). The combined organic extracts were washed with water (50ml), the solvent evaporated, then ethyl acetate (25ml) was added and the solvent re-evaporated. The resultant oil was dissolved in ethyl acetate (35ml) and petroleum ether (200ml) was added slowly. The suspension was cooled to 4°C and the solid product collected by filtration. Recrystallisation from hot ethyl acetate (50ml) and diisopropyl ether (150ml) afforded the title compound as a yellow solid (6.1g) m.p. 118°C.
Intermediate 74
IQ Ethyl 1 — f f 3-bromo-2-(2-nitrophenyl)-5-benzofuranyl]methy1)-4cyclopropyl-2-ethyl-lH-imidazole-5-carboxylate
Intermediate 73 (75g) and Intermediate 13 (38g) were stirred in Ν,N'-dimethylacetamide (450ml), potassium carbonate (50.4g) was added and the mixture stirred at room temperature for 3 days. Ethyl acetate (750ml) and water (750ml) were added and the separated aqueous layer further extracted with ethyl acetate (750ml). The combined organic extracts were washed with water (300ml), IM hydrochloric acid (300ml), water (300ml) and brine (300ml). The ethyl acetate layer was evaporated in vacuo to a volume of 150ml and the resulting suspension stirred overnight. Recrystallisation from diisopropyl ether (450ml) afforded the title compound as a nearly white solid (74.3g) m.p. 95°C.
Intermediate 75
Ethyl 5-cyclobutyl-4-oxazolecarboxylate
The title compound was prepared according to the method of Intermediate 12(a) from ethyl isocyηoacetate and cyclobutylcarboxylic acid chloride.
T.l.c. System A (1:2) Rf=0.25
Intermediate 76
1-f [ 3-Bromo-2-( 2-nitrophenyl)-5-benzofuranyl) methyl 1-4-cyclopropyl2-ethyl-S-iodo-lH-imidazole
AP Ο Ο Ο 3 1 8
CV323/C
- 45 A stirred mixture of Intermediate 74 (2.18g), IN aqueous sodium hydroxide (40.5ml), and methanol (122ml) was heated at reflux for 2h, the methanol was evaporated, brine (82ml) and dichioromethane (112ml) were added and the aqueous phase adjusted from pH 13.7 to pH 12.0 by addition of 5N hydrochloric acid. A solution of iodine (1.03g) in dichioromethane (32ml) was added dropwise to the stirred mixture over 3min, keeping the aqueous phase between pH 11 and pH 12 by simultaneous dropwise addition of IN aqueous sodium hydroxide. The mixture was stirred at ambient temperature for a further 5min and the aqueous phase adjusted to pH 6.7 by addition of 5N hydrochloric acid. Aqueous sodium metabisulphite was added and the organic solution was dried and evaporated. The residue was purified
IQ by column chromatography eluting with System F (40:1). The resulting solid was crystallized from dichloromethane/diisopropyl ether to give the title compound as a yellow, crystalline solid (2.22g) m.p. 180-182°.
Intermediate 77
1- f [ 3-Bromo-2-(2-nitrophenyl)-5-benzofuranyllmethyl)-4-cyclopropyl2- ethyl-lH-imidazole-5-carbonitrile-13C
A stirred mixture of Intermediate 76 (0.570g), potassium (^3CJ cyanide (0.051g), and copper (I) iodide (0.030g) in dry DMF (4ml) was heated at 150° under nitrogen for 15 hours. Ethyl acetate (80ral) was added and the resulting solution was washed with 1% w/v aqueous iron (III) chloride (160ml). The aqueous phase was reextracted with ethyl acetate (40ml) and the combined organic phases was washed with water (160ml), sodium metabisulphite (lg) in water (160ml), water (160ml) and brine (160ml) then dried and the residue purified by column chromatography eluting with ethyl acetate:cyclohexane (1:2). The residual oil was triturated with ether to give the title compound as a yellow crystalline solid (0.326g) m.p. 116-118’.
Intermediate 78
1- ff 2-(2-Aminophenyl)-3-bromo-5-benzofuranyl1methyl)-4-cyclopropyl2- ethyl-lH-imidazole-5-carbonitrile-^3C
jgAD ORIGINAL
CV323/C
- 46 A mixture of Intermediate 77 (0.134g), iron filings (3.0g), acetic acid (0.85ml), water (0.85ml) and ethanol (25ml) was stirred under reflux for 2.5h. The mixture was filtered through celite which was then washed with dichloromethane (40ml). The combined filtrates were evaporated and the residue was dissolved in dichloromethane (50ml) washed with aqueous sodium bicarbonate (50ml), dried and evaporated. The residue was purified by column chromatography eluting with System D (4:1). The resulting solid was recrystallised from acetonitrile (1ml) to give the title compound as a white, crystalline solid (0.089g) m.p. 168-171°.
Example 1
Ethyl 1 — f F3-bromo-2-[2-(1H-tetrazol-5-yl)phenyl1-5-benzofuranyll methyl1-4-eyelopropyl-2-ethy1-1H-imidazole-5-carboxylate Cone. Hydrochloric acid (0.5ml) was added to a solution of Intermediate 19 (2.0g) in ethanol/dichlororaethane (1:1) (30ml) and the mixture was stirred at room temperature for llh. Sodium bicarbonate (8%;10ml) was added and the solvent evaporated. The residue was partitioned between water (10ml) and ether (3x15ml). The aqueous phase was acidified to pHl with 2N HCl (ca 3ral) and extracted with ethyl acetate (3x15ml). The combined ethyl acetate extracts were washed with brine (20ml) and dried. The solvent was evaporated to give the title compound as a colourless foam (1.17g)
m. p. 132-137°.
T.l.c. System F (10:1) Rf 0.7.
Similarly prepared was:25
Example 2 — f f3-Bromo-2-f 2-(lH-tetrazol-5-yl) phenyl]-5-benzofurany1)methyl)-2cyclopropyl-4-methyl-lH-imidazole-5-carboxylic acid
n. m.r. (DMSOdg) δ 1.0-1.1 (4H,m), 2.1-2.3 (lH,m), 2.4 (3H,s), 5.85 (2H,s), 7.18 (lH,dd), 7.33 (lH,brs), 7.54 (lH,d), 7.75-7.85 (2H,m),
7.9-8.0 (2H,m).
m.p. 190-195°C (dec).
From cone, hydrochloric acid (0.25ml) and a solution of Intermediate
AP Ο Ο Ο 3 1 8
CV323/C
- 47 Example 3
Ethyl 1-[f3-bromo-2-[2-f f(trifluoromethyl)3ulphonylIaminolphenyll-5benzofuranylImethyl1~4-cyclopropyl-2-ethyl-lH-imidazole-5carboxylate
A 1M solution of trif1uoromethanesu1phonic anhydride in dichloromethane (4ml) was added dropwise to a stirred solution of
Intermediate 23 (2.01g) in dichloromethane (45ml) containing triethylamine (0.7ml) at -73° under nitrogen. After stirring for 45 mins at -73°, further trifluoromethanesulphonic anhydride (IK in dichloromethane, 2ml) was added dropwise. After 15 mins, water (15ml) was added and the cooling bath removed. After wanning to room temperature, further water (25ml) was added and the separated organic phase was dried and concentrated in vacuo to afford a pink foam (2.4g). Purification by chromatography (Neutral alumina, Grade 3) eluting with ether increasing to ethersacetic acid (49:1) afforded the title compound (1.75g) as an off-white foam.
T.l.c. ether Rf 0.7 15 n.m.r. (DHSOdg) 5 0.9-1.05 (ra,4H), 1.12 (t,3H), 1.23 (t,3H), 2.6 (m,lH), 2.73 (m,2H), 4.25 (q,2H), 5.7 (s,2H), 7.1-7.7(m,8H).
Example 4 l-f f 3-Bromo-2-[2-(lH-tetrazol-5-yl) phenyl1-5-benzofuranylImethyl 1 -4cyclopropyl-2-ethyl-lH-imidazole-5-carboxylic acid
Potassium hydroxide (1.2g) in water (5ml) was added to a suspension of the product of Example 1 (0.5g) in ethanol (15ml) and the mixture stirred at 55° for 18h. The solvent was evaporated and the residue partitioned between water (25ml) and ether (3x25ml). The aqueous phase was acidified to pHl with hydrochloric acid (2N, 15ml) and extracted with ethyl acetate (3x30ml). The combined ethyl acetate extracts were washed with brine (50ml) and dried. The solvent was concentrated in vacuo resulting in the precipitation of a colourless solid which was filtered off and washed with ether (2x5ml) to give the title compound as a colourless solid (290mg) m.p. 198°. n.m.r. (DMSOdg) 5 0.93 (d,2H), 1.12 (t,3H), 2.68 (q+a; 4H), 5.71 (S,2H), 7.06 (dd,lH), 7.12 (S,1H), 7.53 (d,lH), 7.81 (m,2H), 7.95
CV323/C
- 48 Example 5 — f f3-Bromo-2-[2-[[(trifluoromethyl)sulphonyl)amino]phenyll-5benzofuranyllmethyl)-4-eyelopropyl-2-ethy1-1H-imidazole-5-carboxy lie acid
A mixture of the product of Example 3 (1.72g) and 2N aqueous sodium hydroxide (15ml) in methanol (30ml) was stirred at room temperature $ for 6h. After standing overnight, the solution was diluted with further 2N aqueous sodium hydroxide (10ml), stirred for a further 2h at room temperature and then heated at 40° for 90 mins. After cooling, the solution was diluted with brine (80ml) and water (50ml) before being washed with ether (100ml). The aqueous phase was then
1θ acidified with 2N hydrochloric acid to pHl and the cloudy solution was extracted with ethyl acetate (3x90ml). The combined ethyl acetate extracts were dried and concentrated in vacuo to afford the title compound (1.72g) as an off-white foam.
T.l.c. System F(10:l) Rf=0.45 (streaking to 0.25)
n.m.r.(DMSOdg) β 1.1-1.2 (m,7H), 2.7 (m,lH), 3.0 (q,2H), 5.88 15 (s,2H), 7.2 (dd, IH), 7.4-7.8 (m,6H).
Example 6 — f f3-Bromo-2-f2-f[(trifluoromethy!) sulphonyl) amino)phenyl]-5benzofuranyllmethyl]-4-eyelopropyl-2-ethyl—1H-imidazole-520 carboxamide
Concentrated aqueous ammonia (10ml) was added to a solution of Intermediate 26 (0.4g) in ethanol (10ml) and the mixture stirred for 16h at room temperature. The ethanol was evaporated in vacuo and the residue partitioned between hydrochloric acid (0.5M; 25ml) and ethyl acetate/ethanol (10:1) (3x25ml). The combined organic extracts were washed with water (2x25ml) and dried. The solvent was evaporated in vacuo to give a colourless foam which was triturated under ether (3x10ml) to give the title compound as a colourless solid (251mg). T.l.c. System F (10:1) Rf 0.5.
n.m.r. (DMSOdg) δ 0.95-1.15 (m+t;7B), 2.21 (m,lH), 3.05 (q,2H), 5.77 (S,2H), 7.27 (dd,lH), 7.48-7.75 (m,6H), 8.13 (brs,2H).
Example 6 was also prepared by the following alternative method: ·''
AP Ο Ο Ο 3 1 8
CV323/C
- 49 Example β (alternative method)
1-f f 3-Bromo-2-f 2-((( trifluoromethyl)eulphony11 amino)phenyl)-5benzofuranylImethyl1-4-cyclopropyl-2-ethy1-1H-imidazole-5carboxand.de
1,1'-Carbonyldiimidazole (14.3g) was added in one portion to a solution of the product of Example 5 (18g) in dry THF (600ml) at room temperature under nitrogen. The mixture was stirred for 16h, then ammonia was bubbled through the solution for 30mins, and the mixture then stirred for 5h. Ammonia was again bubbled through the reaction mixture for 30mins, and the solution stirred for a further 16h. The reaction mixture was diluted with ethyl acetate (1 litre) and cooled in an ice-bath. Cold dilute hydrochloric acid (0.25M ca. 1 litre) was added dropwise to the vigorously stirred reaction mixture until pH6 was achieved. The aqueous phase was separated and extracted further with ethyl acetate (3x500ml). The combined organic extracts were washed with brine (2x800ml) and dried. The solvent was evaporated to give a colourless foam (18g) which was triturated under ether (250ml) and filtered to give a colourless amorphous solid (13.8g), m.p. 155.6-159.2*.
T.i.c. System F (10:1) Rf 0.5
Example 7
-1-((3-Bromo-2-f 2-((( trifluoromethyl) sulphonyl1 amino]phenyl1-5benzofuranyl Imethyl 1-4-cyclopropYl-2-ethyl-N-methyl-lH-imidazole-5carboxauid.de
A mixture of Intermediate 26 (0.48g) in ethanol (5ml) and 40% aqueous methylamine (20ml) was heated at reflux for 6h. After cooling, the mixture was partitioned between ethyl acetate (60ml), brine (30ml) and water (20ml). The separated aqueous phase was further extracted with ethyl acetate (50ml) and the combined organic extracts were washed with IN hydrochloric acid (2x50ml), water (2x50ml) dried and concentrated in vacuo to afford the title compound (0.31g) as a white solid.
T.i.c. System F (9:1), Rf 0.75.
n.m.r (DMSOdg) S 0.8-1.05 (m,4H), 1.2 (t,3H), 2.07 (m,lH), 2.79 (d,3H), 3.0 (q,2H), 5.63 (s,2H), 7.0-7.6 (m,8H), 8.6 (m,lH).
-Mew»·? ijawaiT1·^». -- ·. ... T... —
BAD ORIGINAL d
CV323/C
- 50 Example 8
1-f[3-Bromo-2 -f 2-[[(trifluoromethyl)sulphonyl1amino]phenyl]-5benzofuranyl]methyl1-4-cyclopropy1-2,N-diethyl-lH-imidazole-5carboxamide
A solution of Intermediate 26 (300mg), THF (10ml) and ethylamine 70% solution in water (2ml) was stirred at room temperature for 18 hours. The solvent was removed in vacuo and the residue dissolved in ethyl acetate (15ml). The ethyl acetate layer was washed with brine (3x15ml), dried and concentrated in vacuo to give an oil. This was purified by flash column chromatography, eluting with System F (20:1) to afford the title compound as an off-white solid (llOmg).
1θ T.l.c. System F (10:1) Rf 0.48
m. p. 124-130°C.
Example 9 — f f3-Bromo-2-f 2-(lH-tetrazol-5-yl)phenyl]-5-benzofuranyl)methyl]-2ethoxy-4-methyl-lH-imidazole-5-carboxaldehyde
From Intermediate 25 (180mg) and cone. HCl (0.5ml) in methanol/THF (1:1) (20ml) according to the method of Example 1. Purification by column chromatography eluting with dichloromethane:ether:hexane: acetic acid (100:100:100:15) gave the title compound as a white solid (20mg).
T.l.c. System E (10:10:1) Rf 0.46
n. m.r. (CDCl3) δ 1.29 (3H,t), 2.12 (3H,s), 4.25 (2H,q), 5.27 (2H,s), 7.1-7.4 (3H,m), 7.5-7.7 (2H,m), 7.84 (lH,m), 7.96 (lH,m).
Examples 10 to 12 in Table 3 were prepared according to the method of Example 3 (Equation 3):
AP Ο Ο Ο 318
CV323/C
- 51 Examples 13 to 20 in Table 4 were prepared according to the method of Example 5 (Equation 4):
Examples 21 and 22 in Table 5 were prepared according to the alternative method of Example 6, utilising ammonia or the appropriate alkylamine (Equation 5):
Examples 23 to 34 in Table 6 were prepared according to the 20 alternative method of Example 6, utilising ammonia or the appropriate alkylamine (Equation 6):
Example 35
2-f 3-Bromo-5-((4-cyclopropyl-2-ethyl-5-[(ethylamino)carbonyl1-1H-
Ρ >. Ρ f. dft
CV323/C
- 52 A solution of the product of Example 24 (0.175g) in dry trifluoroacetic acid (4ml) was stirred at ambient temperature for 1.5h. The solvent was evaporated in vacuo. The residue was dissolved in dichloromethane (50ml) and washed with water (50ml) (pH adjusted to 5 with aqueous sodium carbonate). The organic extract was dried and evaporated to give a solid residue which was crystallized from ethyl acetate/hexane to give the title compound as a white solid (0.12g) m.p. 182-4*.
T.l.c. System F (10:1) Rf=0.4.
Examples 36 to 49 and 66 in Table 7 were prepared according to the method of Example 35 (Equation 7):
Examples 50 to 57 in Table 8 were prepared according to the alternative method of Example 6, utilizing the appropriate alkylamine (Equation 8):
Example 58
4-Cyclopropyl-N,2-diethyl-l-f(2-(2-(f(trifluoromethyl) sulphonyl 1 aminoIphenyl1-5-benzofuranyllmethyl]-lH-imidazole-5-carboxaaide
A solution of the product of Example 8 (0.25g) in ethyl acetate (15ml) was stirred under a hydrogen atmosphere over 10% palladium on carbon (0.3g; 50% aqueous paste) at room temperature for 3h. Solid
AP Ο Ο Ο 3 1 8
CV323/C
- 53 sodium carbonate (70mg) was added and the reaction continued for a further 4h. The mixture was filtered and the filtrate evaporated. The residue was purified by column chromatography eluting with System F (20:1) increasing to (5:1) to give the title compound as a white powder (O.llg), m.p. 165-172*.
T.l.c. System F (9:1) Rf 0.65
Example 59a — f f3-Bromo-2-f 2-f f(trifluorornethyl) sulphonyl) amino)phenyl1-5benzofuranylImethyl)-4-cyclopropyl-2-ethy1-1H-imidazole-5carboxamide, sodium salt
Sodium hydroxide (0.25M in ethanol; 3.27ml) was added dropwise to a solution of the product of Example 6 (0.5g) at 60’ under nitrogen. The solution was cooled to room temperature, then concentrated in vacuo (to 3ml). Ether (20ml) was added, resulting in the precipitation of a colourless powder. The ether was decanted and fresh ether (20ml) added. The solid was filtered and dried to give the title compound as a colourless solid (397mg).
n.m.r. (DMSOdg) 8 0.88 (4H,m), 1.15(3R,t), 2.17 (IB,a), 2.77(2H,q),
5.61 (1H,S), 6.91 (lH,m), 7.11(lH,dd), 7.29 (3H,m), 7.50 (2H,m),
7.62 (2H,br.s).
Assay Found: C,44.4; H,3.3; N,8.0;
c25H21BrF3NaN4°4s·2h2° requires* C,44.85; H,3.7; N,8.4%
Example 59b
1-((3-Bromo-2-[2-(((trifluorornethyl) sulphonyl]amino 1 phenyl1-5benzofuranyl!methyl!-4-cyclopropyl-2-ethyl-lH-imidazole-5carboxamide, potassium salt
Potassium hydroxide (IM in ethanol; 0.16ml) was added to a solution of the product of Example 6 (O.lg) in ethanol (5ml) at room temperature. The mixture was stirred for lh, and the solvent concentrated in vacuo (to 0.5ml). Ether (5ml) was added, resulting in the precipitation of a colourless solid which was filtered off, washed with ether (2x5ml) and dried to give the title compound as a colourless solid (70mg).
CV323/C c k r ” η ΠΑ
- 54 n.m.r. (DMSOdg) δ 0.90 (4H,m), 1.15(3H,t), 2.16 (lH,m), 2.81 (2H,q), 5.62 (lH,s), 6.92 (lH,m), 7.13 (lH,dd), 7.30(3H,m), 7.45 (lH,d), 7.55 (lH,d), 7.71 (2H,br.s).
Assay Found: C,43.55; H,3.7; N,7.7;
c25H21BrF3KN4°4s-2.5H2° requires: C,43.2; H,3.8; N,8.1%
Example 59c $ 1-f[3-Bromo-2-f 2 — f Γ ftrifluoromethyl) sulphonyl1 aminolphenyl]-5benzofuranyllmethyl1- 4-eyelopropy1-2-ethyl-1H-imidazole-5carboxamide, ammonium salt
Concentrated aqueous ammonia (0.2ml) was added to a solution of the product of Example 6 (50mg) in ethanol (1ml) at room temperature.
IQ The mixture was stirred for 30min, then the solvent was evaporated. The residue was triturated under ether (2ml) and filtered to give the title compound as a colourless solid (50mg), m.p. 135-142*.
Assay Found: C,45.4; 8,4.4; N,10.4;
c25B25BrF3N5°4S*2H2° requires: C,45.2; H,4.4; N,10.5%
Examples 60 and 61 in Table 9 were prepared according to the method of Example 35. Examples 62 and 63 in Table 9 were prepared according to the alternative method of Example 6 using ammonia. Examples 64 and 65 in Table 9 were prepared according to the method of Example 5 (see Table 9 with reference to the formula shown below):
Examples 62 and 63: Examples 64 and 65:
RJ = co2h
CO2Me
-. CONH2; and -. CO2H].
Example 68
AP Ο Ο Ο 3 1 8
CV323/C
- 55 Ethyl 4-eye 1 opropy1-2-ethy1-1-[ (3-methoxycarbonyl-2-[2 (methoxycarbonyl) phenyl]-5-benzofuranyl1methyl1-1H-imidazole-5carboxylate
Triethylamine (0.56ml) was added to a solution of the product of Example 67 (see Table 2c) (lg) in DMF (10ml), methanol (10ml) and THF (3ml). Palladium acetate (163mg) and 1,3 bis(diphenylphosphino)propane (299mg) were added and the system sealed under carbon monoxide. After heating at 75*C for 25h the solution was concentrated in vacuo and partitioned between ethyl acetate (50ml) and 10% lithium chloride solution (2x50ml). The dried organic layer was concentrated in vacuo and the residue purified by flash chromatography eluting with System A (3:2) to give the title compound as a white foam (551mg). m.p. 105-110*C {decomp) T.l.c. System A (2:1) Rf 0.38
Example 69 l, 1-Dimethylethyl 2-f 3-bromo-5-f(2-ethyl-4-cyclopropyl-lH-imidazoll-yl)methyl-2-benzofuranylbenzoate
The product of Example 17 (lOOmg) was placed in a flask and stirred at 160°C for 1.5h (40°C above melting point). The resulting gum was dissolved in ethyl acetate (25ml), washed with water (2x25ml), dried and evaporated to give the title compound as an orange gum (58mg).
T.l.c. System G{90:10:1) Rf = 0.46
n.m.r. (CDCl3) δ 0.69 (ra,2H), 0.82 (m,2H), 1.24-1.28 (m,12B), 1.85 (ra,lH), 2.68 (q,2H), 5.1 (s,lH), 6.5 (s,lH), 7.07 (m,lH), 7.32 (d,lH), 7.42 (d,lH), 7.59 (m,2H), 7.7 (m,lH), 7.95 (m,lH).
Similarly prepared was :Example 70
N-f 2-f 3-Bromo-5-f(2-ethyl-4-cyclopropyl-lH-imidazol-l-yl)methyl1-2benzofuranyl1phenyl1-2,2,2-trifluoromethanesulphonamide
From the product of Example 5.
m. p. 284-285°C
CV323/C
- 56 Example 71
Ν— f 2 — f3-Bromo-5-(f 5-(cyano-13C)-4-cyclopropyl-2-ethyl-lH-imidazol-lyl]methyl 1-2-benzofuranyllphenyl)-2,2,2-trifluoromethanesulphonamide A solution of Intermediate 78 (0.066g) and triethylamine (0.029g) in dichloromethane (27ml) was cooled to -70* with stirring under nitrogen. A solution of trifluoromethanesulphonic anhydride (0.045g) in dichloromethane (1.8ml) was added and the mixture $ allowed to warm to ambient temperature. Triethylamine (0.015g) in dichloromethane (lml) then trifluoromethanesulphonic anhydride (0.0235g) in dichloromethane (0.9ml) were added. The mixture was cooled to -70° and trifluoromethanesulphonic anhydride (0.0235mg) in dichloromethane (0.9ml) added. The mixture was again allowed to
IQ warm to ambient temperature. Hater (50ml) was added and IN aqueous sodium hydroxide added to adjust the aqueous phase from pH 1 to pH 5. The dichloromethane phase was dried. The solvent was evaporated and the residue was purified by column chromatography eluting with System F (20:1). The residue was triturated with ether to give the title compound as a beige foam (0.066g).
T.l.c. System F (10:1) Rf 0.64 vmax (nujol)2161, 1203, 1143, 603 cm-^.
Example 72
1-f f 3-Bromo-2-f 2-f f (trifluoromethyl) sulphonyl) aminolphenyl)-5benzofuranyllmethyl)-4-cyclopropyl-2-ethyl-ΙΗ-imidazole-5carboxamide-£2c
To the product of Example 71 (0.253g) was added concentrated aqueous ammonia: water 1:1 (26ml), methanol (5ml) and 27.5% w/v hydrogen peroxide (11ml) and the mixture was stirred at ambient temperature for 80 minutes. Ethyl acetate (150ml) and water (100ml) were added and the aqueous phase acidified from pH 10.8 to pH 2.0 by cautious addition of UN hydrochloric acid (20ml). The organic extract was washed sequentially with sodium metabisulphite (9g) in water (100ml), water (100ml) and brine (100ml) and then dried. Solvent 30 was evaporated and the residue purified by column chromatography eluting with System F (10:1). The residue was crystallized from a mixture of ethanol and water to give the title compound as a white, crystalline solid (0.167g) m.p. 208-210*.
’ 'ί»**»'
AP Ο Ο Ο 3 1 8
CV323/C
- 57 T.l.c. System F (5:1) Rf 0.62.
Example 73
Ethyl 1-[ f 2-[2-[[(trifluoromethyl)sulphony1) amino) phenyl)-5benzofuranyl)methyl1-4-cyclopropy1-2-ethyl-ΙΗ-imidazole-5carboxylate
The title compound was isolated from the product of Intermediate 40 5 and was purified by column chromatogrpahy eluting with System A (1:1).
m.p. 98-102°C T.l.c. ether Rf = 0.6 |() The compounds of the invention are tested in vitro for angiotensin II receptor antagonism. Aortic strips are obtained from male New Zealand white rabbits and prepared for recording isometric contractions in response to cumulative addition of angiotensin II. The potencies of test antagonists are assessed by measuring their abilities to displace the angiotensin II cumulative concentration response curve. The method used is that of Ackerly et al., Proc. Natl. Acad. Sci., 74.(12), pp5725-28 (1977) with the exception that the final composition of the physiological salt solution is as given below in Table 1:
TABLE 1
Ingredient
Amount (mM)
Na+
K+
Mg
Ca
2+
2+
Cl- hpo4~ so4 2~ hco3“ glucose
143.4
5.9
0.6
1.3
124.5
1.2
0.6
25.0
11.1
CV323/C
- 58 ascorbic acid 0.1
The tissues are initially challenged with K+ (80mM) and then washed at 0, 5, 10 and 15 minutes after the response to K+ has plateaued. After a further 45 minutes an angiotensin II cumulative response curve is constructed (O.lnM to Ο.ΙμΜ in 10-fold increments) and the tissues are washed as before. A second, third and fourth angiotensin II cumulative response curve (O.lnM to Ο.ΙμΜ in 3-fold increments) is then constructed at hourly intervals (15 minutes washing after each curve followed by 45 minutes equilibration). The compounds of the invention (30μΜ) are tested for angiotensin II receptor antagonism by application 45 minutes before construction of the fourth angiotensin II curve. The third and fourth angiotensin II curves are expressed graphically and a concentration ratio (CR) is calculated by dividing the angiotensin II EC50 value obtained in the presence of the test antagonist (i.e. fourth curve) by the angiotensin II EC50 value obtained in the absence of the test antagonist (i.e. third curve).
The potency of the test antagonist is expressed as a pKb which is calculated from the equation :
CR-1 pKb = - log [antagonist] which is a rearrangement of equation 4 described by Furchgott, in Handbook of Exp. Pharmacol., 33, p290 (1972) (eds. Blaschko and Muscholl).
If a compound supresses the maximum response to angiotensin II, a pKb is estimated using the double reciprocal plot technique for insurmountable antagonists, described by T.P. Kenakin, Pharmacol. Rev., 36(3), pp!65-222 (esp. 203-204) (1984).
Compounds of the invention will desirably exhibit a pKb in the range between 5 and 12. Thus we have found that the compounds of the invention inhibit the action of the hormone angiotensin II and
oBV
CV323/C
- 59 10
APΟ 00 3 1 8 are therefore useful in the treatment of conditions in which it is desirable to inhibit angiotensin II activity. In particular, the compounds of the Examples are active in the above test.
There is thus provided as a further aspect of the invention a compound of general formula (I) or a physiologically acceptable salt, solvate or metabolically labile ester thereof for use in the treatment of conditions associated with excessive or unregulated angiotensin II activity.
In a further or alternative aspect of the invention there is provided a compound of general formula (I) or a physiologically acceptable salt, solvate or metabolically labile ester thereof for the manufacture of a therapeutic agent for the treatment of conditions associated with excessive or unregulated angiotensin II activity.
There is also provided in a further or alternative aspect of the invention a method for the treatment of conditions associated with excessive or unregulated angiotensin II activity in a mammal including man comprising administration of an effective amount to a mammal in need of such treatment a compound of general formula (I) or a physiologically acceptable salt, solvate or metabolically labile ester thereof.
In addition, by virtue of their antagonistic activity at angiotensin II receptors, compounds of the present invention will be of value in the treatment of conditions associated with activation of the Renin-Angiotensin System.
There is thus provided a further aspect of the present invention a compound of general formula (I) or a physiologically acceptable salt, solvate or metabolically labile ester thereof for use in the treatment of a condition associated with activation of the Renin-Angiotensin system.
In a further or alternative aspect of the present invention there is provided a compound of general formula (I) or a physiologically acceptable salt, solvate or metabolically labile ester thereof for the manufacture of a therapeutic agent for the treatment of a condition associated with activation of the Renin-
ς * ? ,Ί ’ ' Ο A
CV323/C
- 60 There is also provided in a further or alternative aspect of the present inventions a method for the treatment of a condition associated with the activation of the Renin-Angiotensin System in a mammal including man comprising administration of an effective amount to a mammal in need of such treatment of a compound of general formula (I) or a physiologically acceptable salt, solvate or metabolically labile ester thereof.
The following examples illustrate pharmaceutical formulations according to the invention. The term ’active ingredient’ is used herein to represent a compound of formula (1).
Pharmaceutical Example 1
Oral Tablet A
Active Ingredient 70 Omg
Sodium starch glycollate lOmg
Microcrystalline cellulose 5 Omg
Magnesium stearate 4 mg
Sieve the active ingredient and microcrystalline cellulose through a 40 mesh screen and blend in a appropriate blender. Sieve
2Q the sodium starch glycollate and magnesium stearate through a 60 mesh screen, add to the powder blend and blend until homogeneous. Compress with appropriate punches in an automatic tablet press. The tablets may be coated with a thin polymer coat applied by the film coating techniques well known to those skilled in the art. Pigments may be incorporated in the film coat.
Pharmaceutical Example 2
Oral Tablet B
Active Ingredient SOOmg Lactose lOOmg Maize Starch 50rag
AP Ο Ο Ο 3 1 8
CV323/C
- 61 Magnesium stearate mg
Tablet Weight
667mg
Sieve the active ingredient, lactose and maize starch through a 40 mesh screen and blend the powders in a suitable blender. Make an aqueous solution of the polyvinyl pyrrolidone (5 - 10% w/v). Add this solution to the blended powders and mix until granulated; pass the granulate through a 12 mesh screen and dry the granules in a suitable oven or fluid bed dryer. Sieve the remaining components through a 60 mesh screen and blend them with the dried granules. Compress, using appropriate punches, on an automatic tablet press.
The tablets may be coated with a thin polymer coat applied by film coating techniques well known to those skilled in art. Pigments may be incorporated in the film coat.
Pharmaceutical Example 3
Inhalation Cartridge
Active Ingredient Lactose lmg 2 4 mg
Blend active ingredient, particle size reduced to a very fine particle size (weight mean diameter ca. 5pm) with the lactose in a suitable powder blender and fill the powder blender into No. 3 hard gelatin capsules.
The contents of the cartridges may be administered using a powder inhaler.
Pharmaceutical Example 4
Injection Formulation
Active ingredient Water for injections B.P.
to % w/v 1.00
100.00
Sodium chloride may be added to adjust the tonicity of the solution and the pH may be adjusted to that of maximum stability a·®»** 'BAD ORIGINAL ft)
CV323/C
- 62 and/or to facilitate solution of the active ingredient using dilute acid or alkali or by the addition of suitable buffer salts. Antioxidants and metal chelating salts may also be included.
The solution is prepared, clarified and filled into appropriate sized ampoules sealed by fusion of the glass. The injection is sterilised by heating in an autoclave using one of the acceptable cycles. Alternatively the solution may be sterilised by filtration and filled into sterile ampoules under aseptic conditions. The solution may be packed under an inert atmosphere of nitrogen.
bad
AP 0 0 0 3 1 8
Table la (see Equation la)
9A . \
-64Table lb (see Equation lb)
in
o \ο
η
ο
Ct I
«Η μ
·. X
OO ιη
.. CJ
o r—t •
in ο
rH r—1
'— I
υ < μ
ct
ε ε
Φ Φ W
μ μ Φ
<0 Λ χ:
>1 μ
co co Φ
μ o υ υ
Γ—1 Ή
• • •
Q e-> Η Η
Μ
CM CM
r* 1 1 »μ
O -Η ο
□ Μ
ω CM
ϋ □
<Ν CJ
X X
VO μ υ ο
CC ω 1 1
<—1 μ Μ Μ
ct ω CQ CQ
ε CJ m Ch
o τΤ co νο
M ♦ •
U> μ μ μ
C C C
Μ W Μ
O
z
4J
c Γ* αο σ\
CO CO co
\
Ap 0 0 0 3 1 8
Table 2a (see Equation 2a)
m
« 4Ρ r*
·« 4P ΙΟ to •
00 o\ • • ο
• • m in I
m m Ή
X X X
X X ·*
·«, >« rd «
to •Η • ro
• • Ο ··
♦ ro Ο Γ- **4
CO r* Γ*· *—*
r* «» «. α
o υ >· W
u • · σ
σ φ Ε
• · 0) ·· U 0)
•o •σ 4J
c C ro 9)
3 ro 3 ο >,
o o ο r-d C/5
M-i b* Ο
σ\ σι «
>, rH >, ιΗ υ
<0 <0 X (0 X •
4J 95 Ο σ> ο Ή
rtj <0 04 Λ Οί »
o < ο < ο Η
TT »Η ·—ί
X fcy ο ο
3 3
CQ 1 X ) φ
•U 4J Σ
OJ ΟΙ Οί
ro o ο ο
Dd υ υ ο
e ro CO ΓΟ
o *9·
M • • •
lu 4J U 4J
c C G
K Μ Μ
o
z
•U
c to θ' 00
w «r *9·
BAD ORIGINAL &
-66<? I 1 ’ ft a q A
Table 2b (see Equation 2b)
<n
m ao
MT MT •
• m o
o o I
1 1 o *4-4
M-i *M 1 cd
cd cd *p
«
a
m MT ··
« > CO
r—4 t—4 •
*-* f—4
< <
<
£ E E
Φ V E Φ
P a> p
CO 00 p 00
>1 > 00 >1
ω co >, co
co
a υ a a
<0 • • • •
4J r—1 f—1 Γ-( e—4
<0 • • »
Q £-< H (->
*T <“4 r-4
cd lu U υ a
3 □
m (9
Φ 1 1 Φ
X P P X
OJ <N OJ Ol
co o o o o
X u o a u
r—1 M M
cd OQ X X ffl
m co r- ao
MT MT MT MT
e • • • •
O 4J P P P
c c c c
U w w w H4
O
2
4J
c σ\ o cH Ol
M MT m in m
\ :<ί*ιηη·
AP Ο Ο Ο 3 1 β\ \
-67- \ \
uo
*r •Ή
<0 • •
. o o
o 1 1
I MM MM
<u cc 0d
αζ «··»
a cM r4
rH • «·
·· r4 cM
CM —*
< < < υ
E E E ο
Φ 0) Φ KD
4-> 4-> 4-1 5T
«0 CO m o ·) •Η
>1 >1 »—t CM > 1
co w « « 00 m
τΓ
• • • • • »—1
o o M M o
• • • • •
4-> H ^4 E E α
<e •
Q Eh EH c c Eh ε
3 3
CD 1 4J 4J 0 V
Hp U3 ω 4J ω
CM CM CM CM CM
CO o o o o o
cc o υ υ υ o
•KT #4 r-|
cc Lu ω o u X
3 □
CQ ffi
Φ 1 Φ Φ
Σ JJ u X Σ
CM CM CM CM CM
co o o o o o
cd υ o υ o υ
«—t M M M
(C 0 X X 0 0
co CO co
KD cM i-M KD r—1
4- + + + +
σ\ o ^-4 CM O
in m m r*
e ¢0 co co co co
o 4-> 4-» 4-> P u
M c c c c c
U. w W H M w
Γ-
• KD
o •
2 o
♦ 2
U •
c co m KD X
M m m m *n ω
4**r*^' ί*’· riMWs^ ~7jiM)>>.y*»MWi»i
-\
BAD ORIGINAL ft
-68Table 3 (see Equation 3)
AP 0 0 0 3 1 8;
-69Table 4 (see Equation 4)
co
« «
M >,
Φ « «
Λ 9)
P «0
o < <
o o
o o
m VP
rH co
rH rH
<0 • 1 1
•U Q. cr» tT
<0 ♦ o CO
Q E «Η rH
co *3*
I rH «Τ
M-4 •
Ο c£ O o
CM
in
E ·«
fl) o rH
4J o ··
CM σ»
*·»
<n 0 ω
M M 3 1 1
CL CL CD !
Γ* 1 1 1
£X υ O a
M 3 P
cu CQ cu
vp 1 1 |
(X c c c
3 3 3
CO ffl CD
P P P
CM CM CM
co o o o
& 0 o a
rH u p ρ
Λ CO co CD
σ» o rH i
·· CM co CO j
E • • 1
o p P kJ J
M c c c
tu w «Η ♦H i
1 J
o
z
X co U0 i
ω rH «Η <H 1
.<(e^sc?9k^ i
θ'·»*»\
BAD ORIGINAL d
Γ» ί» n q λ
-70e u
e a
M e
x
P o
«Ί
« r* m
« < r* d
o d
«1 u ♦
• a. rM a
V) < JO «
• U 0
£ «a »«/ •
M ♦ ♦ tf
c « *C X
X 2 X C
cj
I σι o
•ύ o
en d
I *Λ u
d <x>
CU u
«
Table 4 (continued)
CM
g ** rM r· in rM <n d Ο rM •o
in in
d vo in
a n in d in • •
MM • • • • © o
o d o © © ©
•
x—*
in CM
· M
o o
·—4 *-* rM Φ
a r· •X
tl o «» rM o rM o
p o o — o ·* o
e rM 9i rM Oi rM
> x^> χ*»
V) o Fx Ix cj b. *u
H k 0 lM u u
CM cm a a a CM
C*· 1 1 1 1 1 rM
et u υ 0 o u ‘H CJ
3 b
a a
υ 0
kl u 1 1
0. CM d d
10 1 P P P X X
ctf 0 H c fa w o o
1 1
3 en en en
CQ [x fa fa
1 U υ υ
P X d d d
β P CM <s o X o o
cn V o 0 ta d ta ω
0£ f* υ CJ X o X X
X u X X
X
rM u u b d
CC a a a M o b Ll
υ Λ a
d n
·· η en in o β> rM d
a » « rM rM 10 r-4
δ P P • • « • «
kl c e X X X X X
h ►M M H u Μ u H
AP 0 0 0 3 1 8
Table 5 (see Equation 5)
Other r· * « n « 4 v0 PM « >1 « « Q 4 m Cl « M 6 C
O
O
in
n
• 1
Ot o
♦ n
e «Η
«
+»
Q
n <n «η
II r* m m X»
• U4 • • • •
u Λ © o o o
a
rK
•
-***
e «4 »·
e — «4 •M ©
© ·· «« o
« 9t «-4
(Q fc. b. th th
Cl
s
o ci Γ4
o h—* s X
z z Λ z
o o O o
Λ u o u V
t* u h kl
et D. 0. 0.
1 1
u u •H o
3 u
a Ch
1 1
o o
1
Cl Cl
X X
±> •μ o υ
tt n CU i
4J M kl u
X w Q a β
o ιΑ
e 4Π r* f*
o • • • •
Ll X X X X
fc. u u u «
0
z
•
X «< Ci <0 r*
M CM Cl P* c·
·φΊ> νΒ*Λ·**%·βϋβΒ&«»» /
AP 0 0 0 3 1 8
Table 6 (see Equation 6)
J,
BAD ORIGINAL
AP 0 0 0 3 1 8
Table 6 (continued)
Other CM rH « CO i-4 « «Ρ «
o u
o o
cm co
co XT
rM w
<X σ* so
• CM
£ <—( r4
p
<0
Q CTi SO r·
m Ό CM Xj*
<4-1 ♦ • «
a tf o o O o o
rP
ε tn «—4
4) P P « «—4 •«
P V Φ m ·« o
V) JC X xr rP
>1 P P —·
v> Φ Φ o Hi tf
P
tf
co
U, o x
O tf 1 tf tf
CM CM CM CM CM
X X X X o
o o υ a to
X X X X X
2 2 2 2 Z
00 o O O O o
x u U O υ u
p P p P P
CU tf tf tf X
Γ* 1 1 1 1
tf a υ υ o u
P
tf
Ό P P P 1 P
tf W ω ω c Ci]
.. Γ* Γ* r- co r*
ε r-4 r-4 r-4 r-l fp
o • • • • •
P X X X X X
tu ω b] w ω ω
Ο
2
X
ω o CM CO
co CO CO co co
BAD original 4
Table 7 (aee Equation 7)
AP I) 0 0 3 1 8
-75Table Ί (continued)
ί Other I_____
υ υ u υ a
o o o o o
Γ- vo in o
ro o vo Γ* co
CM CM rM rH rM
Q. to <n CO O r*
ro o VO r* a>
ε CM CM r4 cM
4J
(0
Q
00 «-Μ m in
I VO CM C* CM CM
U-i • • • •
Λ o O o o o
υ
•
rM rH
O O ί
e rH r-<
0) ·· «· • · »« • »
4J o o O o o
<0 r—I cn rH «—4
«—* '»-*·
co U, o o Cl4
M
CL
£ o •C
a I CL Dm
CM CM CM CM
X X X o
u υ υ to
X X X X X
2 2 2 2 CM
co O O O O o
cC O o υ a a
M M M M M
CL CL Di 0i Du
1 1 1 I I
a: υ υ υ o u
M □
Ol X
vo AJ 4-> 1 AJ I
a£ Cd Cd C Cd c
c4 CM co *r
ε CO CO co co «—4
o • • • • •
M X X X X X
L· Cd Cd Cd Cd Cd
O
2
X VO r* co σν vO
Cd «Τ VO
BAD ORIGINAL •1 C* f
Table 8 (see Equation 8)
Other 1_ .
u u u u u υ υ
o o o o o o o
o co cr» cn CM © cn
sD cn σ\ CM cn cn
<-4 CM υ i-4 CM CM CM ^4
. 1 0 1
Q, m SD o p* O ao co r4
m cn *—1 as CM CM cn cn
e ,-4 CM CM r4 CM CM CM r*4
<0
4->
A3
o CM ’T sD SD m m
I cn in CM CM CM
M-l • • • • •
<C o O © o © O o ©
a
·—t
CM CM un in r4 m
o O © o i—4 o o
«—1 r4 r4 • · «—1 ,-4
ε ·· • · «· ι-M
Φ o o o O ·· ·· o ©
4-> © o o o © O © ©
«0 r—I CM r4 f—1 co CM f-4 r4
>, - >—» *-* --- ——»
ω 0 0 0 0 0 Cl, 0 0
CM
cn
cn X
X cn V
u X X
*-* u cn I
X Cl- SZ u X
υ u u CL 1 CL
CM CM CM CM CM CM
4-> X 4J X X X X X
U υ ω u υ u υ o
X X X X X X X X
2 z z z z z z z
co o o o o o o o o
X o u υ o o υ υ 0
Li Li M Ll M Li Li n
Cl- CL CL CL CL CL CL CL
(-- 1 1 1 1 1 1 1 1
CC υ u υ υ υ u a υ
u Ll L|
CL CL CL
SD 4-) 4J 1 4-) 4-) 4-) 1
tf ω ω c c ω ω u c
SD SD SD
ε «Τ »-4 r4 ST *r ,-4
o Li X X X X X X X X
Lu ω ω Ul ω ω ω ω ω
O
z
X o r*4 CM cn m SD Γ-
ω m in tn m m m in un
i
AP Ο Ο Ο 3 1 8
-77Table
Other VO «-Χ « -4 ex CM * M 6 • e in ex * k £ C
u u o
0 o o
m ϋ VO CD
o 0 n «0
ex »A *x ex
• e* 1 (
a, «X n iA
O ex n *
e 1 ex e* «μ ex
0
μ
ο I ... V
«u • •
• Λ 1 1 o o
ο
*
r-4
• •H
Ρ· «*
e •4 •4
V o o
4-» VA VA
0 «X
>1
W 1 u o
ex ex fX ex
X X a » X X
ex ex X X z X
o o o o o o o
a£ o u υ o o Cl
xr F-< rX
Λ ba O Im o ba o
Φ Φ Φ Φ
X X s s X X
<M ex ex ex ex ex
n o o o o o o
ee o o υ o o u
n VO
·· m lA o «-Χ ex n
e » • VO VO vo vo
0 u • « • •
b c c X X X X
ha M M M fa) u ω
0
X
X O •X ex <*» in
u 4© VO vo VO VO vo
ί υ?': ;; Μ4
-78ι
Table 10
Rf«0.46 r- rH «
n
r—4 un
o o
OJ
·—*
Ul UH
υ υ QC υ
g o o 0
0) σ» GO Ui CD
4-> cn ι—4 Φ OJ
<O rH rH rH
>, | 4-1 J
tn Γ- tO Φ to
cn rH Ol
rH «—4 rH
u u
Λ3 • •
4-> »—1 ά a, rH a
«5 . . * • •
Q H g g H g
4J AJ 4-) AJ aJ
ω ω ω ω ω
OJ Ol OJ OJ Ol
GO o o o o o
a* o υ u υ υ
Ui Ul □ Ul
CU CU OQ cu cn
o* I 1 1 1 Ul
a: υ -H υ υ υ
3 3
CD CQ
ϋ u
Ul Ol ui 3 OJ
CU X CU ffl X
to 1 u 1 1 υ
ex: c 1 c c 1
o
z
4-)
c o* ao cn o rH
HI m m in to to
AP Ο Ο Ο 3 1 8
tl Assay found; C, 63.6; . H, 5.9; N, 4.2 ;
c33H37BrN2°5 requires: C, 63.8; H, 6.0; N,4.5%
*2 solvent was DMSO instead of DMF
.3 Assay found: C,62.6; H,5,5; N,4.4;
c30H3lBrN2°5 requires: C,62.2; H,5.4; N,4.8%
*4 Assay Found: C,62.8, H,5.75; N, 4.4 ;
C31H33BrN2°5 requires : C,62.7; H,5.6; N,4.7%
n.m.r. (CH3OH-d4) δ 0.9 <7H,m), 1.48 (2H,m), 1.97 (3H,s), 2.65 (2H,m), 2.79 (lH,m), 5.81 (2H,s), 7.09 (lH,m), 7.18 (lH,d), 7.3 (2H,d), 7.58(2H,m),7.8<2H,m).
*6 isolated as the acetate salt.
*7 Assay found: C,50.0; H,4.1; N, 8.6;
^27H26BrF3N4®4B requires: C,50.2; H,4.1; N,8.65%
n.m.r. <CDC13) δ 0.9-1.05 (7H,m), 1.2-1.25 (12H,m), 1.63 <2H,m), 1.98 (lH,m), 2.59 (2H,m) 3.45 (2H,m), 5.67 (2H,s), 6.38 (lH,br.t) 7.08 (lH,m), 7.23 (lH,d), 7.36 (lH,d), 7.55 (2H,m), 7.69 (lH,m), 7.92 (lH,m).
n.m.r. (CDC13) δ 0.85-0.95 (7H,m), 1.3 (9H,s), 1.4 (2H,m), 1.68(4H,m), 2.73 (2H,t), 3.45-3.65 (8H,br.m), 5.30-5.50 (2H,br), bad ORIGINAL ό
- 80 7.05 (lH,d), 7.22 (lH,s), 7.40 (lB,d), 7.5-7.65(2H,ra),
7.7(lH,d), 7.93 (18,d).
»10 n.m.r. (CDCl3) δ 0.95 (3H,t), 1.26(98,s), 1.67 (2H,m),
2.02(28,m), 2.3(2H,m), 2.55-2-65 (4H,m), 3.78(lH,m), 5.5(2H, br.S,, 5.63 (2H,9), 7.04 (lH,m), 7.22 (lH,d), 7.37 (lH,d), 7.56 (2H,m), 7.69 (18,m), 7.93 (lH,m).
*11 n.m.r. (CDCl3) δ 0.95 (3H,t), 1.18 (3H,t), 1.25 (9H,s),
1.65(2H,m), 1.9-2.1(2H,m),2.28 (2H,m), 2.51 (2H,m),
2.66 (2H,m), 3.4 (2H,a), 3.68 (lH,m), 5.57-5.6 (3H,m), 7.08(lH,m), 7.26 (lH,d),
7.36 (18,d), 7.56 (2H,m), 7.69 (lH,m), 7.92 (lH,m).
•12 n.m.r. (CDCl3) δ 0.24 (2R,m), 0.52 (2H,m), 0.98-1.08 (4H,m),
1.2 (3H.t), 1.25 (9H,s), 2.02 (lH,m), 2.64 (2H,q), 3.28 (2H,m),
5-67 (2H,s), 6.58 (IH, br.t), 7.08 (lH,m), 7.24 (lH,d), 7.36 (lH,d), 7.5-7.6 (2H,m), 7.67 (lH,m), 7.92 <lH,a).
•13 n.m.r (CDClj) δ 0.92 (3H,t), 1.02-1.07 (4H,m), 1.25 <9H,s),
1.64 (2H,m), 1.98 (lH,m), 2.59 (2H,m), 3.44 (2H,m), 5.67 (28,s), 6.38 (lH,br.t), 7.08 (lH,m), 7.23 (lH,d), 7.37 (lH,d), 7.55 (28,ro), 7.69 (lH,m), 7.93 (lH.m).
»14 n.m.r (CDCl3) δ 1.1-1.3 (16H,m), 2.24 (lH,m), 2.62 (28,q),
5.55 (2H,s), 6.88 (lH,dd), 7.1 (ΙΗ,ε), 7.28 (lH,s), 7.46-7.62 (58,m), 7.69 (lR,d), 7.93 (lH,d), 8.07 (2H,d), 9.16 (lH,br.S).
»15 n.m.r. (CDC13) δ 0.9-1.1 (4H,m), 1.18 (3H,t), 1.28 (3H,t). 1.6 (9H,S), 2.58-2.7 (3H,m), 4.2S(2H,q), 5.58 (2H,s), 6.97.0(2H,m), 7.14 (lH.br.s), 7.35-7.42(3H,m), 7.68 (lH,dd).
used without isolation - see Ex 62.
AP Ο Ο Ο 3 1 8
Η
ΟΗ
-CO2Et *18 *19 *20 *21 .22 *23 *18 *19 *20 *21 .22 *23 and subsequently dehydrated as described in Intermediate 62 to give the required imidazole.
Intermediate 36 is an iaida2ole-S-carboxaldehyde derivative which is converted to the acid as described in Intermediate 68.
n.m.r. (CDCl3) δ 1.24-1.33 (98,m), 1.68-1.88 (4Η,π»Τ, 1.97-2.08 (2H,m), 2.69(18,m), 2.81(28,m), 3.62(lH,m), 4.23 (28,q), 5.63 (28,S), 7.02(18,ra), 7.12(lH,d), 7.4-7.56(38,m), 7.69 (lH,a), 7.83(18,m).
n.m.r. (DHSOdg) δ 0.85-0.95 (48,m), 1.13 (3H,t), 1.47 (98,s), 2.5-2.7 (3H,a), 3.8 (3H,s), 5.65(28,8), 7.15 (lH,dd), 7.28 (IB,br.s), 7.68-7.85 (3H,m), 8.14 (lH,dd).
used without purification - see Ex. 61.
n.m.r. (C0cl3) δ 0.18 (2H,m), 0.55 (2H,m), 1.05 (lH,m), 2.63 (28,d), 5.69 (28,s), 7.05 (lH,dd), 7.21 (18,d), 7.44 (lH,ddd), 7.5S (lH.ddd), 7.68 (lH,dd), 7.70 (lH.br.s), 7.82 (lH,dd).
n.m.r. (CDCl3) δ 0.18 (2H,m), 0.55 (2H,m), 1.05 (18,m), 2.62 (2H,d), 5.68 (lH.br.s), 5.77 (2H,s), 6.68 (18,br.s) 7.06 (18,dd), 7.22 (18,d), 7.43 (lH,d), 7.45 (lH.ddd), 7.55 (lH.ddd), 7.69 (lH,dd), 7.84 (lH,dd), 8.0 (IH, br.s).
n.m.r. (DMSOdg) δ 0.9 (28,m), 1.4 (38,t), 2.16-2.21 (18,a), 2.92 (2H, br.q), 5.7 (28, br.s), 7.23 (lR,d), 7.4-7.8 (58,m), 7.8-8.0 (2H,m).
Ο Γ ,* >· η Ο Λ
-81a»25 n.m.r. (CDjOD) δ 0.95 (2Η,τη), 1.15-1.3 (5H,m), 2.1-2.25 (lH,m), 3.05 (2H,q), 5.77 (2Η, br.s), 7.32 (Η.dd), 7.5-7.7 (4H,m), 7.9 (lH,dd).
*26 Assay found C.50.55; H,4.3; N,8.1;
C28H28Br?3N4°4S'0'3H2° re9uires C.51.0; H,4.4; N,8.5%
The following further Examples have also been made:
Intermediate 79
2-(5-Methyl-2-benzofuranyl)benzoic acid
Intermediate 7 (lO.Og) was suspended in glycerol and heated to 120°C under an atmosphere of nitrogen. Solid potassium hydroxide (12.0g) vas added, in portions, and the reaction mixture was heated to 170°c. After 3 hours the mixture was cooled and poured into water (200ml). 2M hydrochloride acid (100ml) was added dropwise, with stirring, to the solution. The resulting yellowish solid, vas isolated by filtration and dried in vacuo to afford the title compound (12.05g,.
T.i.c. hexane:ethyl acetate:acetic acid (15:5:1) Rf = 0.43
Intermediate 80 (t)-3-Chloro-5-methylepirofbenzofuran-2(3H),1 ’ (3 H)-isobenzofuran ]3 -one
Intermediate 79 (11.95g) was dissolved in 1,4-dioxane (300ml) and water (4ml) was added. The mixture was placed under an atmosphere of nitrogen. N-chlorosuccinimide (7.67g) was added to the stirred solution which was then heated at reflux for 1.5 hours. The mixture was cooled to room temperature, diluted with ethyl acetate (300ml) and vashed vith brine (3x300ml). The organic solution vas concentrated in vacuo to afford a solid (20.2g) which was triturated with methanol (350ml) and filtered to give the title compound (7.229) as a white solid.
T.i.c. System J (1:3) Rf =0.49.
Intermediate 81
2-(3-Chloro-S-methyl-2-benzofuranyl)benzoie acid
bad
AP Ο Ο Ο 3 1 8
-81bInterraediate 80 (7.13Sg) was suspended in toluene (250ml) and 1,8diazabicyclof5.4.Ojundec-7-εηβ (4.58g) wae added slowly over a five minute period. The suspension was warmed to 45°C and stirred for 3 hours. The solution was then heated at reflux for 1 hour. The reaction mixture was cooled, diluted with toluene (500ml) and shaken with hydrochloric acid (250ml) and brine (250ml). The organic layer wa· dried and concentrated in vacuo to afford the title compound (6.78g) as a yellow solid.
T.l.c. hexane:ethyl acetate:acetic acid (15:5:1) Rf 0.50
Intermediate 82
1,1-Pimethylethyl f 2-(3-chloro-5-methyl-2-benzofuranyl)phenyl] carbamate
Froa Intermediate 81 according to the method of Intermediate 5. T.l.c. System A (1:16) Rf * 0.25.
Intermediate 83 , 1-Pimethylethyl. [ 2 - [ S - j_b romome t hy 1 ) - 3-c h 1 or o - 2benzofuranyl)phenyl1carbamate
From Intermediate 82 according to the method of Intermediate 6. T.l.c. System A (1:10) Rf - 0.25
Intermediate 84
Sthyl 1 — ff3-chloro-2-f2-f) lb 1-dimethylethoxy) carbonyl 1 amino 1 phenyl) -S-benzofuranyl ] mathyl 1 - 4-cyclopropyl-2-ethyl-lBireidazole-S-carboxylate
From Intermediate 13 and Intermediate 83 according to the method of Intermediate 19.
T.l.c. System A (2:3) Rf = 0.26
Intermediate 85
Ethyl I —f f 2-( 2-aainophenyl)-3-chloro-5-benzofuranynmethyl1-4cyclopropyl-2-ethyl-lH-imidazole-5-carboxylate
From Intermediate 84 according to the method of Intermediate 23. T.l.c. System A (1:1) Rf 0.29
^ADORiGJNAL
-SlcΓ.
Intermediate 86
2,2, 2-Trifluoro-1-f 5-methyl-2-f(2-nitrophenyl·)methoxy lphenyl) ethanone
A solution of 2-nitro benzyl alcohol (6.9g) in 1,4-dioxane (100ml) was added to a mixture of 2,2,2-trifluoro-1-[2-hydroxy-5methyl)phenyl]ethanone (described in European Patent Specification No. 0434249-A, published 26th June 1991) (6.23g), sodium iodide (0.458g) and potassium carbonate (4.64g) in Ν,Ν-dimethylacetamide (60ml). After stirring for lBh, distilled water (500ml) was added and the resultant slurry stirred for 2h. The solid was collected by filtration, washed with 1,4-dioxane/water (1:1) (300ml), water (3x50ml) and oven dried to give the title compound as a pale yellow solid (7.37g).
T.l.c. System A (1:6) Rf 0.38
Intermediate 87
2,3-Pihydro-S-methyl-2-(2-nitrophenvl)-3-(trifluoromethylj-3benzofuranol (cis & trans diastereolsomers)
Sodium methoxide (246mg) was added to a cooled (0*C) solution of the Intermediate 86 (4.363g) in Ν,Ν-dimethylacetamide (40ml) and stirred for 3h. Distilled water (100ml) was added and the aqueous layer extracted with ethyl acetate (2x100ml; BOml). The combined organic extracts were washed with water (80ml) and 10% aqueous lithium chloride solution (2x100ml), dried and the solvent removed in vacuo to give an oil. Purification by flash column chromatography eluting with System A (1:10 - 1:3) gave the title compounds as pale yellow solids (1.33g; 2.11g).
T.l.c. System A (1:3) Rf 0.42 and Rf 0.21
Intermediate 88
5-(Bromomethyl)-2-(2-nitrophenyl)-3-(trilfluoromethyl)benzofuran
A solution of the diastereoisomers ci Intermediate 07 (5.727g) in acetic anhydride (50ml) and cone, sulphuric acid (5 drops) was heated at reflux for 4.5h. After cooling the solution was
AP Ο Ο Ο 3 1 8
-8Ldremoved in vacuo to give the title compound as a brown solid (5.69g).
T.l.c. System A (1:1) Rf 0.61
Intermediate 89
5-(Bromomethyl)-2-(2-nitrophenyl)-3-(trifluoromethy!)benzofuran
From Intermediate 88 according to the method of Intermediate 11. T.l.c. System A (1:3) Rf » 0.33.
Intermediate 90
Ethyl 4-cyclopropyl-2-ethyl-l-r[2-(2-nitrophenyl)-3(trifluoromethy!)-5-benzofuranyllmethyl]-lH-imidazole-5-carboxvlate
Sodium hydride (60% dispersion, 0.5g) was added to a stirred solution of Intermediate 13 (2.4g) in DMF (100ml). After stirring for 45min under nitrogen, a solution of Intermediate 89 (2.8g) in DHF (50ml) was added dropwise. The reaction was stirred at room temperature for 12h before being diluted with vater (800al) and extracted with ethyl acetate (500ml). The organic extract vas washed with aqueous lithium chloride (3x200ml), dried and concentrated in vacuo to afford a residue. This residue vas purified by flash column chromatography eluting with System F (50:1)-(30:1) to give the title compound (1.6g) as a brown foam. T.l.c. System F (15:1) Rf“0-4.
intermediate 91
Ethyl 1-((2-(2-aminopheny1)-3-(trifluoroaethyl)-5benzofuranyllmethyl]- 4-cyclopropyl-2-ethyl-1B-imidazole-5carboxylate
A mixture of 10% palladium on carbon (lg), vater (30ml), cone. hydrochloric acid (30ml) and a solution of Intermediate 90 (1.4g) in THF (90ml) vas hydrogenated at room temperature for 2h. The mixture was filtered through 'hyflo' and the filtrate vas evaporated in vacuo. The residue was dissolved in dichloromethane (100ml) washed vith sodium carbonate (2N; 500ml), dried and evaporated. The residue was purified by flash column chromatography eluting with System r (75:1) to give the title compound as an off-vhite foam (1.03g).
.**· r .»,
r A s
T.l.c. System A (1:1) Rf
-81e- 0.23.
Example 78
Ethyl l-[ f3-chloro-2-f 2-f f(trifluoromethyl)sulphonyl)aminoIphenyl]S-benzofuranyl1roethy1]-4-cyclopropyl-2-ethy1-1H-imida2ole-5carboxylate
From Intermediate 85 according to the method of Example 3.
T.l.c. ether:acetic acid (200:1) Rf «* 0.63
n.m.r. (CDClj) δ 0.97 (2H,a), 1.8(2H,m), 1.2 (3H,t), 1.3 (3H,t), 2.58-2.72 (3H,tn), 5.64 (2B,s), 7.08 (lH,m), 7.3 (lB,m), 7.41-7.56 (3H,m), 7.7 (lH,m), 7.85 (lB,m).
Example 79
1-f f 3-Chloro-2-[2-(((trifluoromethyl)sulphonyl]amino) phenyl)-5benzof uranyl·! methyl)-4-cyclopropyl-2-ethvl-lH-inu.d3 2ole-5-carboxyllc acid
From the product of Example 78 according to the method of Example 5.
m.p. 164-165°C (decomp)
T.l.c. ethyl acetate Rf =0.46 (streak).
Example 80 l-Γ f 3-ChIoro-2-[2-f f(trifluoromethyl) sulphonyl]amino?phenyl]-5benzofuranyl)methyl]- 4-cyclopropyl-2-ethyl-1B-imidazole-5carboxamide
From the product of Example 79 according to the method of Intermediate 26 followed by the method of Example 6.
T.l.c. System J (1:3) Rf =0.28
n.m.r. (CDClj) δ 1.0-1.1 (4H,a), 1.27 (3H,t), 1.95-2.05 (lH,m), 2.66 (2U,q), 5.69 (2H,s), 7.1 (lB,m), 7.27-7.3 (lB,m), 7.4-7.56(3H,ra), .7 (lH,m), 7.84 (lH,m).
Example 81
Ethyl 1-((3-(trifluoromethyl)-2-(2-f ί(trifluoromethyl)sulphonyl) amino1phenyl1-S-benzofuranyllmethyl1-4-cyclopropyl-2-ethyl-lBimidagole-5-carboxylate
From Intermediate 91 according to the method of Example 3.
T.l.c. ether Rf = 0.65
AP Ο Ο Ο 3 1 8 —8 If—
n.m.r. (CDCl,) 8 0.9-1.1 (ra,4H), 1.18 (t,3H), 1.3 (t,3H), 2.55-2.7 (m,3H), 4.27 (q,2H), 5.2-5.6 (vbr.s, 18), 5.62 (br.*, 23), 7.03 (dd,lH), 7.4-7.75 (m,6H).
Example 82
1-f f 3-( Trifluoromethyl) - 2-f 2-f f(trifluoromethyl)sulphonyl)amino) phenyl 1-S-benzof uranyl lmethyl 1-4-cyclopropyl-2-ethyl-lB-imidazole-Scarboxylic acid
From the product of Example 81 according to the method of Example 5. m.p. 155-158°C
T.l.c. system G (20:2:1) Rf = 0.3
Example 83
1-t (3-(Trif luoromethyl)-2-[ 2-f f (trif luoromethyl) sulphonyl) amino] phenyll-S-benzofuranyl lmethyl l-4-cyclopropyl-2-ethyl-lH-imidazole-5carboxamide
From the product of Example 82 according to the method of Intermediate 26 followed by the method of Example 6. m.p. 183-186°C

Claims (18)

  1. Claims :
    CV323/EP or a physiologically acceptable salt, solvate or metabolically labile ester thereof wherein
    R1 represents a hydrogen atom or a halogen atom or a group selected from C1_6alkyl, C2_galkenyl, fluoroCj_galkyl, C1_galkoxy ,-CHO, -CO2H or -COR2;
    R2 represents a group selected from C1_galkyl, C2_galkenyl, Cj-galkoxy or the group -NR^3R^4;
    R3 represents a group selected from -CO2H, -NHSO2CF3 or a C-linked tetrazolyl group;
    R4 and R5 which may be the same or different each independently represent a hydrogen atom or a halogen atom or a C1_galkyl group;
    Het represents the group
    R6 represents a hydrogen atom or a group selected from Cj galkyl, c2-6alkenY1' c1_6alkylthio, Cj.galkoxy, C3_7cycloalky1 or C3 7cycloalkylC1 4alkyl;
    ORIGINAL
    - 83 represents a hydrogen atom or a halogen atom or a group selected from cyano, nitro, Cj_galkyl, C2galkenyl, f1uoroC|_ga 1ky1, -(CH2)mR9, -(CH2 )nCOR10, -(CH2)pNR11COR12, C3_?eyeloa1ky1 or
    C3_7eyeloalkylCi_4alkyl;
    q
    R° represents a hydrogen atom or a halogen atom or a group selected from cyano, nitro, C1_galkyl, C2_galkenyl, fluoroC_ga Iky1, -(CH2)mR9, -(CH2)nCOR10 or -(CH2)pNR11COR12;
    5 R9 represents a hydroxy or C|_galkoxy group;
    R10 represents a hydrogen atom or a group selected from hydroxy, Cj^alkyl, C1_galkoxy, phenyl, phenoxy or the group -NR^3R^4; rH represents a hydrogen atom or a Cj_galkyl group;
    R^2 represents a hydrogen atom or a group selected from C3_galkyl, C|_galkoxy, phenyl, phenoxy or the group -NR13R14;
    R13 and R14, which may be the same or different, each independently represent a hydrogen atom or a CjL_4alkyl group or -NR13R^4 forms a saturated heterocyclic ring which has 5 or 6 ring members and may optionally contain in the ring one oxygen atom;
    15 m represents an integer from 1 to 4, preferably 1 or 2, especially 1;
    n represents zero or an integer from 1 to 4, preferably zero, 1 or 2, especially zero or 1; and p represents an integer from 1 to 4, preferably 1 or 2;
    20 with the proviso that when R9 represents a hydrogen atom or a group selected from C1_galkyl, C2_galkenyl or C1_galkylthio, R represents a group selected from C3_7cycloalkyl or C3_7cycloalkylC|_4alkyl.
  2. 2. A compound according to Claim 1 or a physiologically acceptable
    25 salt, solvate or metabolically labile ester thereof wherein R^3 and
    R^·4, which may be the same or different, each additionally independently represent, a group selected from Cg_galkyl, fluoroC1_galkyl, C3_7cycloalkyl, C3_7cycloalkylC1_4alkyl, -(CH^gR15 or -SO2R15, wherein R19 represents an aryl group such as a phenyl or pyridinyl group and q represents an integer from 1 to 4, preferably
    1 or 2, especially 1.
  3. 3. A compound as claimed either Claim 1 or Claim 2 wherein R6 represents a hydrogen atom or a group selected from Cj-galkyl,
    AP Ο Ο Ο 3 1 8
    - 84 C3_5alkenyl, Cj_galkoxy, C3_7cycloalkyl or C3_7cycloalkylC1_4alkyl, preferably a Cj.galkyl group, especially an ethyl, n-propyl or nbutyl group or a but-l-enyl group, an ethoxy group, a cyclopropyl or cyclobutyl group or a cyclopropylmethyl group, most preferably an ethyl group.
  4. 4. A compound as claimed in any one of Claims 1 to 3 wherein R7
  5. 5 represents a halogen atom or a group selected from Cj_6alkyl,
    C3_7cycloalkyl or C3_7cycloalkylC1_4alkyl, preferably a chlorine atom or a group selected from methyl, ethyl, propyl, cyclopropyl, cyclobutyl or cyclopropylmethyl.
    5. A compound as claimed in any one of Claims 1 to 4 wherein R® represents a group selected from -(CH2)mR9 wherein R9 is preferably a hydroxy group or a C1_6alkoxy group, especially a methoxy, ethoxy, propoxy or butoxy group, and most preferably a hydroxy or methoxy group, and m preferably represents 1 or 2; or -(CH2)nCOR3® wherein
    15 rIO is preferably a hydrogen atom or a group selected from hydroxy, c^_galkoxy, especially a methoxy, ethoxy, propoxy or butoxy group, or the group -NR13R14 where R13 and R34 each, preferably, independently represent a hydrogen atom or a C3_4alkyl group, and rIO most preferably represents a hydrogen atom or a group selected
    20 from hydroxy, methoxy, amino, methylamino or ethylamino, and n preferably represent zero, 1 or 2, especially zero or 1, most especially zero.
  6. 6. A compound as claimed in any one of Claims 1 to 5 wherein R6
    25 represents an ethoxy, cyclopropyl, cyclobutyl or cyclopropylmethyl group; R7 represents a chlorine atom or a methyl or ethyl group; and o
    R“ represents a group selected from -CH2OH, -CHO, -CH2OCH3, -CO2H, -co2ch3, -co2ch2ch3, -conh2, -conhch3 or -CONHCH2CH3.
  7. 7. A compound as claimed in any one of Claims 1 to 5 wherein R6 represents a C|_galkyl group, preferably an ethyl or propyl group; R7 represents a cyclopropyl, cyclobutyl or cyclopropylmethyl group;
    Q and R° represents a group selected from -CH2OH, -CHO, -CH2OCH3,
  8. 8. A compound as claimed in any one of Claims 1 to 7 wherein R1 represents a hydrogen atom or a halogen atom or a group selected from Cjgalkyl, Cj-galkoxy or fluoroCj_galkyl, preferably a hydrogen atom or a halogen atom or a C3_3alkyl group, most preferably a bromine atom.
    5
  9. 9. A compound as claimed in any one of Claims 1 to 8 wherein the group Het-CH2- is attached at the 5- or 6-position on the benzofuran ring, preferably at the 5- position on the benzofuran ring.
  10. 10. A compound as claimed in any one of Claims 1 to 9 wherein R4 and R5 each independently represent a hydrogen atom or a halogen atom, preferably a hydrogen atom.
  11. 11. A compound as claimed in Claim 2 or a physiologically acceptable salt, solvate or metabolically labile ester thereof wherein
    R1 represents a hydrogen atom or a halogen atom or a group selected from Cj_galkyl, fluoroC1_galkyl, -CO2H or -COR2;
    Ar represents the group
    R2 represents a C1_galkoxy group;
    25 R^ represents a group selected from -CO2H, -NHSO2CF3 or a C-linked tetrazolyl group;
    R4 and R5 which may be the same or different each independently represent a hydrogen atom or a halogen atom or a C1_6alkyl group;
    Het represents the group
    AP Ο Ο Ο 3 1 8
    - 86 r® represents a group selected from Cj_galkyl, Cj_galkoxy, C3_7cycloalkyl or C3_7cycloalkylC1_4alkyl;
    r7 represents a halogen atom or a group selected from C^_galkyl, fluoroC1_6alkyl or C3_7cycloalkyl;
    R® represents a hydrogen atom or a halogen atom or a group selected from cyano, -(CH2)nCOR10 or -(CH2)pNR11COR12;
    represents a hydrogen atom or a group selected from hydroxy, 5 c^_galkoxy or the group -NR^rH.
    R^1 represents a hydrogen atom;
    R12 represents or a group selected from C3_6alkoxy or the group
    -NR13R14; d13 and R*4, which may be the same or different, each independently represent a hydrogen atom or a group selected from C|_galkyl, fluoroC3_6alkyl, C3_7cycloalkyl, C3_7cycloalkylC1_4alkyl, -(CH2)<JR15 or -NR13R14 forms a saturated heterocyclic ring which or -so2r15, has 5 or 6 ring members and may optionally contain in the ring one oxygen atom;
    r!5 represents a phenyl or pyridinyl group; m represents an integer from 1 to 4, preferably 1 or 2, especially l;
    n represents zero or an integer from 1 to 4, preferably zero, 1 or 2, especially zero or 1;
    20 p represents an integer from 1 to 4, preferably 1 or 2; and q represents an integer from 1 to 4, preferably 1 or 2, especially l;
    with the proviso that when R® represents a Cj_6alkyl group, R7 represents a C3_7cycloalkyl group.
  12. 12. A compound as claimed in Claim 1 selected from
    1-(( 3-Bromo-2-[ 2-( 1H-tetrazol-5-yl)phenyl]-5-benzofuranyl ]methyl ]-2cyclopropyl-4-methyl-lH-imidazole-5-carboxylic acid;
    1-( ( 3-Bromo-2-(2-( ( (trifluoromethyl) sulphonyl]amino]phenyl J-5benzofuranylJmethyl]-2-cyclopropy1-4-methyl-lH-imidazole-5carboxamide;
    1-(( 3-Bromo-2-( 2-(( (trifluoromethyl) sulphonyl ] amino] phenyl J-5benzofuranylJmethyl]-2-cyclopropy1-N, 4-dimethyl-lH-imidazole-525
    - 87 OA
    1-((3-Bromo-2-(2-(((trifluoromethyl)sulphonyl]araino)phenyl]-5benzof uranyl jmethyl ] -2-cyclopropyl-N-ethyl-4-methyl-lH-imidazole-5carboxamide;
    1-((3-Bromo-2-(2-(lH-tetrazol-5-yl)phenyl]-5-benzofuranylJmethyl]-4chloro-2-eyelopropyl-lH-imidazole-5-carboxylie acid;
    1-((3-Bromo-2-(2-(((trifluoromethyl) sulphonyl]amino]phenyl]-5benzofuranyl Jmethyl] - 4-chloro-2 -cyclopropyl - 1H_-imidazole- 55 carboxamide;
    1-[(3-Bromo-2-(2-([(trifluoromethyl)sulphonyl]amino]phenyl]-5benzof uranyl Jmethyl]-4-chloro-2-cyclopropyl-N-methyl-lH-imidazole-5carboxamide;
    1-((3-Bromo-2-(2-(((trifluoromethyl) sulphonyl]amino]phenyl J-5benzof uranyl] methyl ]-4-chloro-2-cyclopropyl-N-ethyl-lH-imidazole-5carboxamide;
    1—[f3-Bromo-2-[2-(lH-tetrazol-5-yl)phenyl]-5-benzofuranyl]methyl]-2cyclopropylmethyl-4-methyl-IH-imidazole-5-carboxylic acid;
    1-((3-Bromo-2-[2-(((trifluoromethyl) sulphonyl]amino]phenyl]-515 benzofuranylJmethyl]-2-eyelopropylmethy1-4-methy1-1H-imidazole-5carboxamide;
    1-((3-Bromo-2-[2-(((trifluoromethyl) sulphonyl J aminoJphenyl)-5benzofuranylJmethylJ-2-cyclopropyImethy1-N, 4-dimethyl-lH-imidazole5-carboxamide;
    20 1-[(3-Bromo-2-(2-(((trifluoromethyl) sulphonyl]amino]phenyl]-5benzofuranylJmethyl]-2-cyclopropylmethyl-N-ethyl-4-methy1-1Himidazole-5-carboxamide;
    1-([3-Bromo-2-[2-(lH-tetrazol-5-yl)phenyl]-5-benzofuranyl]methyl]-4chloro-2-eyelopropylmethyl-IR-imidazole-5-carboxylie acid;
    25 1-((3-Bromo-2-(2-(((trifluoromethyl) sulphonyl]amino]phenylJ-5benzofuranylJ methyl]-4-chloro-2-eyelopropyImethy1-N-methy1- 1H_imidazole-5-carboxamide;
    1-((3-Bromo-2-(2-(((trifluoromethyl) sulphonyl]amino] phenyl]-5benzof uranyl Jmethyl ]-4-chloro-2-cyclopropylmethyl-N-ethyl-liiimidazole-5-carboxamide;
    1-((3-Bromo-2-[2-(((trifluoromethyl) sulphonyl]aminoJ phenylJ-5benzofuranylJmethylJ-4-chloro-2-eyelopropyImethy1-1H-imidazole-5-
    AP Ο Ο Ο 3 1 8
    - 88 1-(( 3-Bromo-2-[ 2-( 1Η-tetrazol-5-y1)phenyl ] -5-benzofuranyl ]methyl ] -2ethoxy-4-methyl-ΙΗ-imidazole-5-carboxylic acid;
    1-((3-Bromo-2-(2-[[(trifluoromethyl) sulphonyl]amino]phenyl]-5benzofuranyl]methyl]-2-ethoxy-4-methyl-lH-imidazole-5-carboxamide; 1-(( 3-Bromo-2-[ 2-((( trif lu or ome thyl) sulphonyl ] amino ] phenyl ] - 5benzofuranyl) me thyl) - 2 -ethoxy-i£, 4-dime thy 1-1 H_-imidazole-5carboxamide;
    5 1-(( 3-Bromo-2-{ 2-((( trif luor ome thyl) sulphonyl ] amino ] phenyl ] - 5benzof uranyl ]methyl ] -2-ethoxy-N-ethy 1-4-methyl-lH^-imldazole-5carboxamide;
    1-(( 3-Bromo-2-( 2-( lH-tetrazol-5-yl)phenyl]-5-benzofuranyl]methyl]-4chloro-2-ethoxy-lH-imidazole-5-carboxylic acid;
    1-(( 3-Bromo-2-( 2-((( trifluoromethyl) sulphonyl) amino] phenyl ]-5benzof uranyl ]methyl]-4-chloro-2-ethoxy-lH-imidazole-5-carboxamide; 1-((3-Bromo-2-(2-(((trifluoromethyl) sulphonyl]amino]phenyl]-5benzofuranylJmethyl ] -4-chloro-2-ethoxy-N-methyl-lH-imidazole-5carboxamide;
    1-(( 3-Bromo-2- ( 2-((( trif luor omethyl) sulphonyl ] amino ] phenyl ] - 5benzof uranyl ] methyl ] -4-chloro-2-ethoxy-N-e thyl-lib-imidazole-5carboxamide;
    1-(( 3-Bromo-2- { 2-((( trifluoromethyl) sulphonyl ] amino] pheny 1 ] -5benzof uranyl ] me thyl ] -4-cyclopropy Imethy 1-2 -ethyl-1H-imidazole-520 carboxamide;
    1-(( 3-Bromo-2-( 2-((( trif luoromethyl) sulphonyl ] amino ] phenyl ] - 5benzofuranyl]methyl]-4-cyclopropylmethyl-2-ethy1-N-methyl-lHimidazole-5-carboxamide;
    1-(( 3-Bromo-2- [ 2-((( tri f luoromethyl) sulphonyl] amino] phenyl ] -525 benzofuranyl(methyl]-4-cyclopropyImethy1-N, 2-diethyl-lH-imidazole-5carboxamide;
    1-(( 3-Bromo-2-( 2-((( trif luoromethyl) sulphonyl ] amino ] phenyl ] -5benzofuranyl ] methyl ] - 4-cyclobutyl-2-ethyl-lH_-imidazole-5carboxamide;
    1-(( 3-Bromo-2-( 2-((( trif luoromethyl) sulphonyl ] amino ] phenyl ] -5benzof uranyl Jmethyl ]-4-cyclobutyl-2-ethyl-N-methyl-lH-imidazole-5carboxamide;
    BAD
    - 89 1 —[I 3-Bromo-2-(2-(((trifluoromethyl)sulphonyl]amino]phenyl]-5benzofuranyl ] methyl ] -4-cyclobutyl-N, 2 - d i e t hy 1 - 1 F[-imidazole-5carboxamide;
    1—[[3-Bromo-2-(2-(1H-tetrazol-5-yl)phenyl)-5-benzofuranyl]methyl)-4cyclopropyl-2-ethyl-lH-imidazole-5-carboxylie acid;
    1-((3-Bromo-2-[2-(1H-tetrazol-5-yl)phenyl]-5-benzofuranyl]methyl)-4cyclobutyl-2-ethyl-lH-imidazole-5-carboxylie acid;
    5 1-((3-Bromo-2-[2-(lH-tetrazol-5-yl)phenyl]-5-benzofuranyl]methyl]-4cyclopropyImethyl-2-ethyl-lH-imidazole-5-carboxylic acid;
    1-((3-Bromo-2-[2-(((trifluoromethyl) sulphonyl]amino]phenyl)-5benzofuranyl)methyl]-4-cyclopropyl-2-ethyl-N-methyl-lH-imidazole-5carboxamide;
    1-((3-Bromo-2-(2-(((trifluoromethyl) sulphonyl]amino]phenyl]-5b e η z o f u r a n y 1 ] me t hy 1 ] - 4 - cy c 1 op r o py 1 - 2 - e t hy 1 -1 i mi d a ζ ο 1 e - 5 carboxamide;
    1-((3-Bromo-2-[2-(((trifluoromethyl) sulphonyl]amino]phenyl)-5benzofuranyl]methyl]-4-cyclopropyl-N,2-diethyl-1H-imidazole-515 carboxamide;
    or a physiologically acceptable salt, solvate or metabolically labile ester thereof.
  13. 13. A process for the preparation of a compound as claimed in any 20 one of Claims 1 to 12 or a physiologically acceptable salt, solvate or metabolically labile ester thereof which comprises:
    (Al) treating a compound of general formula (II) wherein L is a leaving group, and R1 and Ar are as defined in general formula (I), with an imidazole of general formula (III)
    R7 (IH) rf
    S'
    AP Ο Ο Ο 3 1 8
    - 90 6 7 8 wherein R , R and R are as defined in general formula (1), followed, if necessary, by the removal of any protecting groups where present; or (A2), where R6 represents a C1_galkoxy group, by treating a compound of general formula (II) with an imidazole of general formula (Ilia)
    OHa) wherein I·' is a leaving group that is displaceable by an alkoxy group under conditions suitable for aromatic nucleophilic substitution followed by conversion into a compound of general formula (I) wherein R® represents a C3_galkoxy group by treatment with an appropriate alkoxide, followed, if necessary, by the removal of any protecting groups where present; or (B) deprotecting a protected intermediate of general formula (IV)
    2q wherein R^, Ar and Het are as defined in general formula (I) except that at least one reactive group is blocked by a protecting group; or (C), where the substituent R3 in the group Ar represents a C-linked tetrazolyl group (and the imidazolyl group represented by Het is not
    25 substituted by a cyano group), reacting a compound of general formula (Ia) wherein R1, Ar and Het are as defined in general formula (I) except that in the group Ar, R3 represents a nitrile group, with an azide, followed, if necessary, by the removal of any protecting grou whe re pre sen t; or
    - 91 «’ Μί» (D), where reacting a the substituent R3 compound of general in the group Ar represents -NHSOjCFj, formula (lb)
    5 wherein R3, Ar and Het are as defined in general formula (I) except that in the group Ar, R3 represents an amino group, with trifluoromethanesulphonic anhydride or trifluoromethylsulphonyl chloride, followed, if necessary, by the removal of any protecting groups where present; or jq (E), where R represents the group -CONHR , by reacting a compound of formula (XIII)
    Het1 - CH,
    Ar (ΧΙΠ) wherein Het3 represents a group of formula in which R® and R7 are as defined in general formula (I) and X is a halogen atom (for example chlorine or bromine), or a hydroxyl or Cj_galkoxy group, with
    25 ammonia (R33 = hydrogen), methylamine (R = methyl) or ethylamine (R33 = ethyl), followed, if necessary, by the removal of any protecting groups where present;
    and when the compound of general formula (I) is obtained as a
    30 mixture of enantiomers optionally resolving the mixture to obtain
    AP Ο Ο Ο 3 1 β
    - 92 and/or, if desired, converting the resulting compound of general formula (I) or a salt thereof into a physiologically acceptable salt, solvate or metabolically labile ester thereof.
  14. 14. A pharmaceutical composition comprising at least one compound of general formula (I) as defined in any one of Claims 1 to 12 or a physiologically acceptable salt, solvate or metabolically labile
    5 ester thereof, together with at least one physiologically acceptable carrier or excipient.
  15. 15. A compound of general formula (I) as claimed in any one of Claims 1 to 12 or a physiologically acceptable salt, solvate or metabolically labile ester thereof for use in therapy, for example, (i) for use in the treatment or prophylaxis of hypertension; or (ii) for use in the treatment or prophylaxis of congestive heart failure, acute or chronic heart failure, aortic or cardiac insufficiency, post-myocardial infarction, renal insufficiency and renal failure (for example, as a result of diabetic nephropathy, glomerular nephritis, scleroderma or renal crisis), proteinuria, Bartter's syndrome, secondary hyperaldosteronism, Reynaud's syndrome, cerebrovascular insufficiency, peripheral vascular disease, diabetic retinopathy, atherogenesis and for the improvement
    20 of vascular compliance; or (iii) for use in the treatment or prophylaxis of cognitive disorders such as dementia (e.g. Alzheimer's disease) and other CNS disorders, such as anxiety disorders, schizophrenia, depression and alcohol or drug (e.g. ***e) dependency;
    25 (iv) for use in the treatment of conditions associated with excessive or unregulated angiotensin II activity; or (v) for use in the treatment of a condition associated with activation of the Renin-Angiotensin System.
  16. 16. A compound of general formula (Ia)
    Het-CHj (Ia)
    BAD ORIGINAL fi or an acid addition salt thereof wherein
    R1, Ar and Het are as defined in Claim 1 except that in the group Ar, R3 represents a nitrile group.
  17. 17. A compound of general formula (lb) jq or an acid addition salt thereof wherein
    R1, Ar and Het are as defined in Claim 1 except that in the group Ar, R3 represents an amino group.
  18. 18. A compound of general formula (lb) as claimed in Claim 17 or an 15 acid addition salt thereof wherein R3 additionally represents a nitro group.
AP9200389A 1991-05-16 1992-05-15 Benzofuran derivatives AP318A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919110636A GB9110636D0 (en) 1991-05-16 1991-05-16 Chemical compounds

Publications (1)

Publication Number Publication Date
AP318A true AP318A (en) 1994-02-15

Family

ID=10695121

Family Applications (1)

Application Number Title Priority Date Filing Date
AP9200389A AP318A (en) 1991-05-16 1992-05-15 Benzofuran derivatives

Country Status (21)

Country Link
US (2) US5332831A (en)
EP (1) EP0514198B1 (en)
JP (1) JPH06211846A (en)
KR (1) KR920021541A (en)
AP (1) AP318A (en)
AT (1) ATE169297T1 (en)
AU (2) AU654350B2 (en)
BG (1) BG98216A (en)
CA (1) CA2068766A1 (en)
CZ (1) CZ243093A3 (en)
DE (1) DE69226472D1 (en)
FI (1) FI935036A (en)
GB (1) GB9110636D0 (en)
IL (1) IL101882A0 (en)
IS (1) IS1609B (en)
MX (1) MX9202281A (en)
NO (1) NO921944L (en)
OA (1) OA09841A (en)
SK (1) SK112893A3 (en)
TW (1) TW221998B (en)
WO (1) WO1992020674A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9218449D0 (en) 1992-08-29 1992-10-14 Boots Co Plc Therapeutic agents
US5336779A (en) * 1992-10-08 1994-08-09 Nippon Gohsei Kagaku Kogyo Kabushiki Kaisha Method of producing formylimidazoles
US6071931A (en) * 1995-10-06 2000-06-06 Novartis Ag AT1 -receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys
ES2189940T3 (en) 1996-02-29 2003-07-16 Novartis Ag AT1 RECEIVER ANTAGONIST FOR THE STIMULATION OF APOPTOSIS.
KR100567183B1 (en) * 1997-11-14 2006-06-13 론자 아게 How to prepare formyl imidazole
NZ587909A (en) 1998-12-23 2012-05-25 Novartis Ag Process of making a compressed tablets containing valsartan and microcrystalline cellulose
US6465502B1 (en) 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
CN101011390A (en) 1999-01-26 2007-08-08 诺瓦提斯公司 Use of angiotensin II receptor antagonists for treating acute myocardial infarction
US6211217B1 (en) 1999-03-16 2001-04-03 Novartis Ag Method for reducing pericardial fibrosis and adhesion formation
AU6019700A (en) * 1999-07-21 2001-02-05 Takeda Chemical Industries Ltd. Preventives for the recurrence of cerebrovascular failure and agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof
SE9903028D0 (en) 1999-08-27 1999-08-27 Astra Ab New use
JP2004506012A (en) * 2000-08-17 2004-02-26 グリアテツク・インコーポレイテツド Novel cycloaliphatic imidazoles as H3 agents
DE10335027A1 (en) 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of telmisartan and simvastatin for treatment or prophylaxis of cardiovascular, cardiopulmonary and renal diseases e.g. hypertension combined with hyperlipidemia or atherosclerosis
ES2560247T3 (en) * 2006-05-05 2016-02-18 Dow Global Technologies Llc Hafnium complexes of heterocyclic organic ligands
PT2090570E (en) 2006-09-05 2011-12-29 Kyowa Hakko Kirin Co Ltd Imidazole derivative
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
JP5072675B2 (en) 2007-04-03 2012-11-14 四国化成工業株式会社 Method for producing 2-haloimidazole compound
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2930674A1 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP2016514670A (en) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase receptor agonists in combination with other drugs
JP6606491B2 (en) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド Ultra high purity agonist of guanylate cyclase C, method for producing and using the same
EA202090205A1 (en) 2017-07-07 2020-06-02 Бёрингер Ингельхайм Ветмедика Гмбх ANGIOTENZINE II RECEPTOR ANTAGONIST FOR PREVENTION OR TREATMENT OF SYSTEM DISEASES IN CATS
CN110256382A (en) * 2019-06-06 2019-09-20 武汉药明康德新药开发有限公司 A kind of synthetic method of 2- (5- methyl benzofuran -2- base) benzonitrile

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028834A1 (en) * 1979-11-12 1981-05-20 Takeda Chemical Industries, Ltd. Imidazole-5-acetic acid derivatives, their production and use
EP0028833A2 (en) * 1979-11-12 1981-05-20 Takeda Chemical Industries, Ltd. Imidazole derivatives, their production and use

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1389827A (en) * 1971-07-23 1975-04-09 Fisons Ltd Tetrazolyl benzopyrans
JPS54148788A (en) * 1978-05-15 1979-11-21 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative and its preparation
US4526896A (en) * 1978-12-26 1985-07-02 Riker Laboratories, Inc. Tetrazol-5-yl 2-nitro-3-phenylbenzofurans and antimicrobial use thereof
AU559687B2 (en) * 1981-07-01 1987-03-19 Upjohn Company, The Pyridinyl-and imidazolyl-benzofurane and benzothiophenes
JPS6163671A (en) * 1984-09-05 1986-04-01 Shionogi & Co Ltd 2,3-dihydrobenzofuran-5-sulfonamide derivative and hypotensive diuretic
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4916129A (en) * 1989-01-19 1990-04-10 E. I. Du Pont De Nemours And Company Combination β-blocking/angiotensin II blocking antihypertensives
EP0955294B1 (en) * 1989-06-14 2003-09-24 Smithkline Beecham Corporation Imidazolyl-alkenoic acid
WO1991000281A2 (en) * 1989-06-30 1991-01-10 E.I. Du Pont De Nemours And Company Fused-ring aryl substituted imidazoles
WO1991000277A1 (en) * 1989-06-30 1991-01-10 E.I. Du Pont De Nemours And Company Substituted imidazoles
JPH03204875A (en) * 1989-10-03 1991-09-06 Wakamoto Pharmaceut Co Ltd Tetrazoleacetic acid derivative and aldose reductase inhibitor comprising same derivative as active ingredient
CA2027937A1 (en) * 1989-10-25 1991-04-26 Richard M. Keenan Substituted 5-¬ (tetrazolyl)alkenyl|imidazoles
CA2028925A1 (en) * 1989-11-06 1991-05-07 Gerald R. Girard Substituted n-(imidazolyl)alkyl alanine derivatives
GB8927277D0 (en) * 1989-12-01 1990-01-31 Glaxo Group Ltd Chemical compounds
US5190942A (en) * 1991-04-22 1993-03-02 E. R. Squibb & Sons, Inc. Benzoxazole and related heterocyclic substituted imidazole and benzimidazole derivatives
MX9202300A (en) * 1991-05-16 1992-11-01 Glaxo Group Ltd DERIVATIVES OF BENZOFURANO, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM.
DE4140519A1 (en) * 1991-12-09 1993-06-17 Merck Patent Gmbh benzofurans

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028834A1 (en) * 1979-11-12 1981-05-20 Takeda Chemical Industries, Ltd. Imidazole-5-acetic acid derivatives, their production and use
EP0028833A2 (en) * 1979-11-12 1981-05-20 Takeda Chemical Industries, Ltd. Imidazole derivatives, their production and use

Also Published As

Publication number Publication date
NO921944D0 (en) 1992-05-15
EP0514198A1 (en) 1992-11-19
DE69226472D1 (en) 1998-09-10
FI935036A0 (en) 1993-11-15
FI935036A (en) 1993-11-15
WO1992020674A1 (en) 1992-11-26
EP0514198B1 (en) 1998-08-05
IS1609B (en) 1996-10-18
ATE169297T1 (en) 1998-08-15
CA2068766A1 (en) 1992-11-17
NO921944L (en) 1992-11-17
SK112893A3 (en) 1994-11-09
IS3865A (en) 1992-11-17
AU1632192A (en) 1993-03-11
CZ243093A3 (en) 1994-03-16
AU654350B2 (en) 1994-11-03
KR920021541A (en) 1992-12-18
BG98216A (en) 1994-08-15
GB9110636D0 (en) 1991-07-03
MX9202281A (en) 1992-11-01
US5332831A (en) 1994-07-26
AU1692692A (en) 1992-12-30
US5498722A (en) 1996-03-12
JPH06211846A (en) 1994-08-02
OA09841A (en) 1994-08-15
IL101882A0 (en) 1992-12-30
TW221998B (en) 1994-04-01

Similar Documents

Publication Publication Date Title
AP318A (en) Benzofuran derivatives
EP0430709A2 (en) Benzthiophen derivatives
NZ236297A (en) Imidazol-1-yl methyl benzofuran derivatives, medicaments, and precursors
EA012431B1 (en) Pyrazole derivatives, pharmaceutical compositions and use thereof
NZ237366A (en) 4-(2&#39;-(tetrazolyl (and carboxy and trifluoromethane sulphonamido)(1,1&#39; biphenylyl)-4-ylmethyl) pyrazole derivatives
WO1992016552A1 (en) 1-imidazolgemethyl benzofuran derivatives as inhibitors of angiotensin ii activity
US5374646A (en) Benzofuran derivatives
US5310927A (en) Benzofuran derivatives
US5317023A (en) Benzofuran derivatives
TWI297683B (en) Diazole derivatives
US8895565B2 (en) Heterocyclic compound and use of the same
JPH06503083A (en) Benzofuran and benzothiophene derivatives
JP5540227B2 (en) Phenylimidazole compound
TW201602089A (en) Polycyclic HERG activators
US5252593A (en) Pyrazole containing benzofuran derivatives and pharmaceutical compositions
IE921565A1 (en) Benzofuran derivatives
NZ242755A (en) Benzofuranyl methyl imidazole derivatives, pharmaceutical compositions
JPH0625250A (en) Thieno(3,4-d)imidazole derivative, its production and pharmaceutical agent for circulatory organ containing the derivative
WO1992020673A1 (en) Antihypotensive benzofuran derivatives with n-linked 1h-imidazolylmethyl-5-carboxamide substituents
JP2003528087A (en) 4-oxo-1,4-dihydro-3-cinnolinecarboxamide as antiviral agent
WO1994011369A1 (en) ANTIHYPERTENSIVE 5-[(IMIDAZO[4,5-b]PYRIDIN-3-YL)METHYL]BENZOFURAN DERIVATIVES
AP185A (en) Benzofuran derivatives
AP254A (en) C-Linked pyrazole derivatives.
SI9200253A (en) Benzofuran derivates
NZ242105A (en) Benzofuran derivatives, preparation, intermediates and pharmaceutical